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I.  General Information 
 
Unless otherwise noted, reagents received from commercial suppliers were used as 
received.  All reactions were performed under an atmosphere of dry nitrogen.  Anhydrous 
THF was purchased from Sigma-Aldrich and stored under nitrogen; other solvents were 
purified by passage through activated aluminum oxide in a solvent-purification system.  
Dimethyl pyridine-2,6-bis(carbimidate) was prepared from pyridine-2,6-dicarbonitrile.1 
NMR spectra were collected on a Varian 300 MHz, a Bruker 400 MHz, or a Varian 500 MHz 
spectrometer at ambient temperature; chemical shifts (δ) are reported in ppm downfield from 
tertramethylsilane, using the solvent resonance as the internal standard.  HPLC analyses were 
carried out on an Agilent 1100 series system with Daicel CHIRALPAK® or Daicel 
CHIRALCEL® columns (4.6 × 250 mm, particle size 5 μm).  SFC analyses were carried out on 
an Agilent 1260 Infinity II system with Daicel CHIRALPAK® or Daicel CHIRALCEL® 
columns (4.6 × 250 mm, particle size 5 μm).  FT-IR measurements were carried out on a 
Thermo Scientific Nicolet iS5 FT-IR spectrometer equipped with an iD5 ATR accessory.  
HRMS were acquired by a Waters LCT Premier XE TOF MS in electrospray ionization (ESI+) 
mode.  LC-MS were obtained on an Agilent 6140 UHPLC-MS system in electrospray 
ionization (ESI+) mode.  Optical rotation data were obtained with a Jasco P-2000 polarimeter 
at 589 nm, using a 100 mm pathlength cell in the solvent and at the concentration indicated.  
GC analyses were carried out on an Agilent 6890N GC.  Column chromatography was 
performed using silica gel (SiliaFlash® P60, particle size 40-63 μm, Silicycle) or acidic Al2O3 
(Brockmann I, 50-200 µm, 60A, Acros Organics).  X-ray crystallographic analyses were carried 
out by the Caltech X-Ray Crystallography Facility using a Bruker APEX-II CCD diffractometer.  
X-band EPR measurements were collected on a Bruker EMX spectrometer. 
 
S–3 
II.  Preparation of Chiral Ligands 
 




yl)pyridine.  An oven-dried 100 mL round-bottom flask was charged with a stir bar and 
fitted with a reflux condenser attached to a nitrogen line.  Next, (1S,2S)-2-amino-1-
phenylpropane-1,3-diol (5.05 g, 30.2 mmol, 2.0 equiv) and dimethyl pyridine-2,6-
bis(carbimidate) (2.92 g, 15.1 mmol, 1.0 equiv) were added, and then the flask was sealed with 
a rubber septum cap.  The flask was placed under a nitrogen atmosphere by evacuating and 
back-filling the flask (three cycles), followed by the addition of 1,2-dichloroethane (25 mL).  
The resulting solution was heated at reflux for 24 h.  Then, the reaction mixture was cooled 
overnight at 5 °C, during which time ((4S,4'S,5S,5'S)-pyridine-2,6-diylbis(5-phenyl-4,5-
dihydrooxazole-2,4-diyl))dimethanol precipitated as a brown solid, which was filtered, dried 
(4.67 g, 72% yield), and directly used in the following reaction. 
A solution of ((4S,4'S,5S,5'S)-pyridine-2,6-diylbis(5-phenyl-4,5-dihydrooxazole-2,4-
diyl))dimethanol (4.67 g, 10.9 mmol, 1.0 equiv), imidazole (4.45 g, 65.3 mmol, 6.0 equiv), and 
DCM (50 mL) was cooled to ~0 °C in an ice/water bath, and TBDPSCl (6.3 mL, 24 mmol, 2.2 
equiv) was added via syringe over 5 min.  The resulting mixture was stirred at room 
temperature for 4 h.  Then, the reaction was quenched with water (50 mL), and the mixture 
was extracted with DCM (50 mL x 3).  The combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  The residue was purified by column 
chromatography on silica gel (1:4 EtOAc/hexanes) to afford the product as a white solid (8.3 g, 
9.2 mmol, 84% yield, >99% ee). 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IF-3 column (30% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for (S,S)-L1: 6.7 min, (R,R)-L1: 8.5 min. 
1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 7.9 Hz, 2H), 7.89 (t, J = 7.9 Hz, 1H), 7.73 – 7.57 (m, 
8H), 7.47 – 7.26 (m, 22H), 5.74 (d, J = 6.7 Hz, 2H), 4.50 – 4.37 (m, 2H), 4.13 – 4.04 (m, 2H), 3.93 – 
3.76 (m, 2H), 1.05 (s, 18H). 
13C NMR (101 MHz, CDCl3) δ 163.0, 147.2, 140.8, 137.4, 135.8, 135.7, 133.4, 133.3, 129.90, 
129.87, 128.8, 128.3, 127.88, 127.87, 126.2, 126.1, 85.0, 76.8, 65.9, 27.0, 19.4. 
S–4 
FT-IR (film): 3419, 2932, 2740, 2355, 1962, 1644, 1574, 1462, 1428, 1360, 1256, 1218, 1112, 965, 
825, 748 cm-1. 
HRMS (ESI+) m/z [M+Na]+ calcd for C57H59N3NaO4Si2: 928.3936, found: 928.3945. 
[]22D = +16.7 (c 1.0, CHCl3), from (S,S)-L1. 
 
  
(1S,2S)-1,2-Bis(2-ethylphenyl)-N1,N2-dimethylethane-1,2-diamine.2  An oven-dried 250 
mL round-bottom flask was charged with a stir bar and (1R,2R)-1,2-bis(2- hydroxyphenyl)-1,2-
diaminoethane (10.0 g, 40.9 mmol, 1.0 equiv), and then it was sealed with a rubber septum cap.  
The flask was placed under a nitrogen atmosphere by evacuating and back-filling the flask 
(three cycles), followed by the addition of anhydrous DMSO (200 mL) and 2-
ethylbenzaldehyde (13.7 g, 102 mmol, 2.5 equiv) via syringe.  After the yellow mixture was 
stirred overnight at room temperature, the reaction was quenched by the addition of water 
(200 mL) and extracted with Et2O (100 mL x 3).  The combined organic layers were washed 
with water (100 mL) and brine (100 mL), and then they were dried over anhydrous Na2SO4 
and filtered.  The mixture was then concentrated under reduced pressure.  2,2'-((1E,1'E)-
(((1S,2S)-1,2-Bis(2-ethylphenyl)ethane-1,2-diyl)bis(azanylylidene))bis-
(methanylylidene))diphenol, obtained as a yellow oil as a mixture with unreacted 2-
ethylbenzaldehyde, was used in the next step without further purification. 
An oven-dried 1000 mL round-bottom flask was charged with a stir bar, and then it was 
sealed with a rubber septum cap.  The flask was placed under a nitrogen atmosphere by 
evacuating and back-filling the flask (three cycles), followed by the addition of a solution of 
crude 2,2'-((1E,1'E)-(((1S,2S)-1,2-bis(2-ethylphenyl)ethane-1,2-diyl)bis(azanylylidene))bis-
(methanylylidene))diphenol (~20 g, ~41 mmol) in THF (630 mL).  A solution of HCl (12 M; 31 
mL) was added to the reaction by addition funnel over 10 min while stirring at room 
temperature.  The reaction was allowed to stir overnight, after which Et2O (200 mL) was 
added.  The diamine was extracted with a solution of HCl (1 M; 100 mL x 4).  The combined 
aqueous phase was washed with Et2O (100 mL) and was then basified with a solution of 
aqueous NaOH (2 M).  The resulting yellow suspension was extracted with Et2O (100 mL x 3).  
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The combined organic layers were washed with water (100 mL) and brine (100 mL), and then 
they were dried over anhydrous Na2SO4 and filtered.  The mixture was concentrated under 
reduced pressure to give (1S,2S)-1,2-bis(2-ethylphenyl)ethane-1,2-diamine (9.2 g, 34 mmol, 
82% yield over 2 steps) as an orange oil. 
A 500 mL two-neck round-bottom flask was charged with a stir bar, a 250 mL addition 
funnel, and potassium carbonate (28.4 g, 206 mmol, 6.0 equiv), and then it was sealed with a 
rubber septum cap.  The flask was placed under a nitrogen atmosphere by evacuating and 
back-filling the flask (three cycles).  A solution of (1S,2S)-1,2-bis(2-ethylphenyl)ethane-1,2-
diamine (9.2 g, 34 mmol, 1.0 equiv) in THF (275 mL) and distilled water (42 mL) were added 
sequentially via the addition funnel.  After the resulting suspension was stirred for 10 min at 
room temperature, ethyl chloroformate (32.6 mL, 343 mmol, 10.0 equiv) was added dropwise 
into the flask via syringe over 10 min.  The reaction was allowed to stir at room temperature 
for 4 days, after which it was diluted with distilled water (200 mL) and extracted with ethyl 
acetate (100 mL x 3).  The combined organic layers were washed with water (150 mL) and 
brine (150 mL), and then they were dried over anhydrous Na2SO4 and filtered.  The mixture 
was concentrated under reduced pressure.  The residue was purified by column 
chromatography on silica gel (3:7 EtOAc/hexanes) to afford diethyl ((1S,2S)-1,2-bis(2-
ethylphenyl)ethane-1,2-diyl)dicarbamate as a white solid (3.7 g, 8.9 mmol, 26% yield). 
An oven-dried 250 mL two-neck round-bottom flask was charged with a stir bar, fitted 
with a reflux condenser attached to a nitrogen manifold, and then sealed with a rubber septum 
cap.  The flask was placed under a nitrogen atmosphere by evacuating and back-filling the 
flask (three cycles).  Lithium aluminum hydride (1.6 g, 43 mmol, 5.0 equiv) was added 
through the open neck under a positive pressure of nitrogen.  The open neck was capped 
with a rubber septum, and the flask was cooled to 0 °C using an ice/water bath.  THF (40 mL) 
was added via syringe, and the gray suspension was stirred at 0 °C for 5 min.  Next, a 
solution of diethyl ((1S,2S)-1,2-bis(2-ethylphenyl)ethane-1,2-diyl)dicarbamate (3.5 g, 8.6 mmol, 
1.0 equiv) in THF (40 mL) was added dropwise via syringe through the rubber septum over 10 
min.  The ice/water bath was replaced with an oil bath, and the reaction mixture was heated 
at reflux for 18 h.  The mixture was cooled to 0 °C using an ice/water bath, and water (4 mL) 
was added dropwise via syringe over 10 min.  Next, a solution of aqueous NaOH (3.0 M; 4 
mL) was added dropwise over 1 min.  The resulting mixture was heated at reflux for 1 h, 
during which the color of the precipitate changed from gray to white.  The warm solution 
was filtered through a Büchner funnel that contained a bed of celite, and the precipitate was 
washed with Et2O (100 mL).  The filtrate was concentrated under reduced pressure to yield 
the crude product as a light-yellow solid.  The crude product was dissolved in EtOH (30 mL) 
and D-tartaric acid (1.29 g, 8.6 mmol, 1.0 equiv) was added.  The heterogeneous mixture was 
stirred at reflux for 30 min, after which it was allowed to slowly cool back to room 
temperature.  The mixture was then cooled to 0 °C, and after 4 h the precipitate was collected 
by filtration and washed with EtOH (5 mL x 2).  The precipitate was added to a mixture of 
10% NaOH in water (10 mL) and Et2O (10 mL).  After stirring overnight, the layers were 
separated, and the aqueous layers were extracted with Et2O (10 mL x 2).  The combined 
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organic layers were washed with water (20 mL) and brine (20 mL), and then they were dried 
over anhydrous Na2SO4 and filtered.  The mixture was concentrated under reduced pressure 
to yield the desired ligand as a white solid (1.59 g, 5.4 mmol, 62% yield, >99% ee). 
SFC analysis: The ee was determined via SFC on a CHIRALPAK ID column (20% i-PrOH in 
supercritical CO2, 2.5 mL/min); retention times for (S,S)-L2: 3.2 min, (R,R)-L2: 4.2 min. 
1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 7.8, 1.5 Hz, 2H), 7.15 (td, J = 7.5, 1.5 Hz, 2H), 7.07 
(td, J = 7.4, 1.5 Hz, 2H), 6.91 (dd, J = 7.6, 1.5 Hz, 2H), 3.91 (s, 2H), 2.46 – 2.33 (m, 2H), 2.23 (s, 
6H), 2.12 – 2.00 (m, 4H), 0.95 (t, J = 7.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 143.2, 138.8, 128.2, 127.0, 126.8, 125.8, 65.3, 34.8, 24.7, 15.5. 
FT-IR (film): 3230, 2967, 2786, 1489, 1106, 874, 764, 741 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C20H29N2: 297.2, found: 297.2. 




III.  Preparation of Electrophiles 
 
The yields have not been optimized. 
 
General Procedure 1 (GP-1). 
  
Preparation of N,O-acetals. An oven-dried 250 mL round-bottom flask was charged with a 
stir bar and the acetal (1.0 equiv; either purchased or prepared from the corresponding 
aldehyde3), and then it was sealed with a rubber septum cap.  The flask was placed under a 
nitrogen atmosphere by evacuating and back-filling the flask (three cycles), and then DCM 
(volume to generate a 1.0 M solution of the potassium phthalimide) and 2,4,6-collidine (3.0 
equiv) were added.  The resulting solution was cooled to ~0 °C using an ice/water bath, and 
then TESOTf (2.0 equiv) was added via syringe over 10 min.  The reaction mixture was stirred 
at ~0 °C for 30 min.  After verifying the consumption of the acetal via TLC, potassium 
phthalimide (3.0 equiv) and 18-crown-6 (3.0 equiv) were added in one portion to the reaction 
mixture under a positive flow of nitrogen, and the solution was stirred at room temperature 
for 2 h.  Then, the reaction was quenched with water, and the mixture was extracted with 
DCM (three times).  The combined organic layers were washed with a solution of HCl (2 M), 
dried over Na2SO4, filtered, and concentrated under reduced pressure.  The residue was 
purified by column chromatography on silica gel to give the N,O-acetal. 
Chlorination of N,O-acetals.  PCl5 (1.5 equiv) was added to a solution of the N,O-acetal 
(1.0 M in 1,2-DCE; 1.0 equiv) at room temperature.  The reaction mixture was stirred at 50 °C 
overnight, and then the reaction was quenched with water.  The organic layer was washed 
with saturated aqueous NaHCO3 (three times), and then it was dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The product was purified either by recrystallization 
(CHCl3/hexanes) or by column chromatography on acidic Al2O3.  The alkyl chlorides used in 
this study are stable after purification and can be stored at room temperature for at least six 
months without decomposition. 
 
General Procedure 2 (GP-2). 
 
Preparation of N,O-acetals.  K2CO3 (1.3 equiv) and the nucleophile (1.3 equiv) were added 
to solution of 2-(6-bromo-1-methoxyhexyl)isoindoline-1,3-dione (0.50 M in DMF; 1.0 equiv; 
synthesized according to the first step of GP-1).  The reaction mixture was stirred at 50 °C 
overnight.  Then, the reaction was quenched with water, and the mixture was extracted with 
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then they were dried over Na2SO4, filtered, and concentrated under reduced pressure.  The 
residue was purified by column chromatography on silica gel to give the N,O-acetal. 
Chlorination of N,O-acetals.  See GP-1. 
 
General Procedure 3 (GP-3). 
 
Preparation of NHP esters.  An oven-dried 250 mL round-bottom flask was charged with 
a stir bar, N-hydroxyphthalimide (1.0 equiv), and DMAP (1.0 equiv), and then it was sealed 
with a rubber septum cap.  The flask was placed under a nitrogen atmosphere by evacuating 
and back-filling the flask (three cycles), followed by the addition of anhydrous DCM (volume 
to generate a 0.2 M solution of the amino acid) via syringe.  The mixture was stirred for 5 min, 
after which the amino acid (1.0 equiv) was added under a positive flow of nitrogen.  After the 
mixture had stirred for an additional 5 min, DIC (1.0 equiv) was added dropwise via syringe 
over 5 min.  The reaction was allowed to stir until the acid was fully consumed (typically 1 h, 
although the reaction can be left to stir overnight with no significant loss in yield).  The 
mixture was filtered through a pad of celite and washed with water.  The organic layer was 
dried over anhydrous Na2SO4 and filtered, and the solution was then concentrated under 
reduced pressure.  Methanol (~5.0 mL/mmol of the amino acid) was added, and the mixture 
was stirred for 5 min.  The mixture was cooled to –25 °C over 4 h, during which a solid 
precipitated.  The solid was filtered and washed with cold methanol, affording the desired 
NHP ester.  The NHP esters used in this study can be stored at room temperature for over 
one year without decomposition. 
 
 
2-(1-Chloroethyl)isoindoline-1,3-dione.  The title compound was synthesized according 
to GP-1 from 1,1-dimethoxyethane (1.80 g, 20.0 mmol).  The product was purified by 
recrystallization.  2.91 g (14.3 mmol, 72% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.96 – 7.84 (m, 2H), 7.84 – 7.71 (m, 2H), 6.29 (q, J = 6.8 Hz, 1H), 
2.16 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.4, 134.8, 131.7, 124.0, 60.3, 23.5. 
FT-IR (film): 3444, 2916, 2354, 1715, 1360, 1033, 876, 721 cm-1. 

























2-(1-Chloropropyl)isoindoline-1,3-dione.  The title compound was synthesized according 
to GP-1 from 1,1-dimethoxypropane (3.12 g, 30.0 mmol).  The product was purified by 
recrystallization.  4.48 g (20.1 mmol, 67% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.85 (m, 2H), 7.82 – 7.73 (m, 2H), 5.99 (t, J = 7.6 Hz, 1H), 
2.66 – 2.46 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 134.8, 131.7, 124.0, 65.7, 29.7, 11.3. 
FT-IR (film): 2978, 2370, 1724, 1458, 1373, 1293, 1064, 1032, 870, 720 cm-1. 
LC-MS (ESI-MS) m/z [M+NH4]+ calcd for C11H14ClN2O2: 241.1, found: 241.1. 
 
 
2-(1-Chloropentyl)isoindoline-1,3-dione.  The title compound was synthesized according 
to GP-1 from 1,1-dimethoxypentane (2.35 g, 17.8 mmol).  The product was purified by 
recrystallization.  2.60 g (10.4 mmol, 58% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 8.01 – 7.84 (m, 2H), 7.84 – 7.70 (m, 2H), 6.07 (t, J = 7.7 Hz, 1H), 
2.66 – 2.41 (m, 2H), 1.54 – 1.21 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 134.8, 131.7, 124.0, 64.3, 35.9, 28.8, 21.9, 14.0. 
FT-IR (film): 3495, 2960, 2369, 1732, 1469, 1366, 1073, 959, 879, 726 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C13H14NO2: 216.1, found: 216.1. 
 
 
2-(1-Chloro-3-methylbutyl)isoindoline-1,3-dione.  The title compound was synthesized 
according to GP-1 from 1,1-dimethoxy-3-methylbutane (2.64 g, 20.0 mmol).  The product was 
purified by column chromatography on acidic Al2O3 (1:3 EtOAc/hexanes).  2.52 g (10.0 mmol, 
50% yield over 2 steps).  Colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.98 – 7.84 (m, 2H), 7.83 – 7.70 (m, 2H), 6.19 (dd, J = 8.3, 7.3 
Hz, 1H), 2.59 – 2.45 (m, 1H), 2.41 – 2.27 (m, 1H), 1.78 – 1.61 (m, 1H), 0.96 (d, J = 6.6 Hz, 3H), 0.95 
(d, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 134.8, 131.7, 124.0, 63.0, 44.5, 25.9, 22.2, 22.0. 
FT-IR (film): 3487, 2915, 2351, 1723, 1360, 1049, 952, 882, 741 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C13H14NO2: 216.1, found: 216.1. 
 
 
2-(1-Chloro-3-phenylpropyl)isoindoline-1,3-dione.  The title compound was synthesized 
according to GP-1 from (3,3-dimethoxypropyl)benzene (3.60 g, 20.0 mmol).  The product was 
purified by recrystallization.  4.10 g (13.7 mmol, 69% yield over 2 steps).  White solid. 
S–10 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.83 (m, 2H), 7.81 – 7.72 (m, 2H), 7.29 – 7.20 (m, 2H), 
7.20 – 7.09 (m, 3H), 6.07 (t, J = 7.4 Hz, 1H), 3.00 – 2.77 (m, 3H), 2.77 – 2.64 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 166.4, 139.6, 134.8, 131.7, 128.7, 128.6, 126.5, 124.0, 63.7, 37.4, 
33.0. 
FT-IR (film): 3488, 3027, 2352, 1721, 1360, 1222, 1081, 966, 876, 736 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C17H14NO2: 264.1, found: 264.1. 
 
 
2-(1-Chloro-3-(4-(trifluoromethyl)phenyl)propyl)isoindoline-1,3-dione.  The title 
compound was synthesized according to GP-1 from 1-(3,3-dimethoxypropyl)-4-
(trifluoromethyl)benzene (4.96 g, 20.0 mmol).  The product was purified by recrystallization.  
5.41 g (14.7 mmol, 74% yield over 2 steps).  White solid. 
1H NMR (500 MHz, CDCl3) δ 7.88 – 7.80 (m, 2H), 7.80 – 7.71 (m, 2H), 7.45 (d, J = 8.1 Hz, 2H), 
7.27 (d, J = 8.3 Hz, 2H), 6.06 (t, J = 7.3 Hz, 1H), 3.03 – 2.81 (m, 3H), 2.82 – 2.69 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 166.3, 143.6, 134.9, 131.4, 128.9, 128.8 (q, J = 26.3 Hz), 125.5 (q, 
J = 3.0 Hz), 124.2 (q, J = 218 Hz), 123.9, 63.4, 36.9, 32.9. 
19F NMR (282 MHz, CDCl3) δ –62.4. 
FT-IR (film): 3495, 2938, 2357, 1731, 1360, 1068, 1019, 719 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C18H13F3NO2: 332.1, found: 332.1. 
 
 
2-(1-Chloro-3-(4-iodophenyl)propyl)isoindoline-1,3-dione.  The title compound was 
synthesized according to GP-1 from 1-(3,3-dimethoxypropyl)-4-iodobenzene (4.08 g, 13.3 
mmol).  The product was purified by recrystallization.  3.4 g (8.0 mmol, 60% yield over 2 
steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.92 – 7.82 (m, 2H), 7.82 – 7.73 (m, 2H), 7.59 – 7.49 (m, 2H), 
6.94 – 6.85 (m, 2H), 6.04 (t, J = 7.4 Hz, 1H), 2.97 – 2.71 (m, 3H), 2.69 – 2.57 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 166.4, 139.2, 137.7, 134.9, 131.6, 130.6, 124.0, 91.7, 63.5, 37.0, 
32.6. 
FT-IR (film): 3484, 2937, 2351, 1722, 1366, 1087, 722 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C17H13INO2: 390.0, found: 390.0. 
 
 
6-Chloro-6-(1,3-dioxoisoindolin-2-yl)hexyl pivalate.  The title compound was 
synthesized according to GP-1 from methyl 6,6-dimethoxyhexyl pivalate (4.10 g, 16.7 mmol).  
S–11 
The product was purified by column chromatography on acidic Al2O3 (1:4 EtOAc/hexanes).  
2.1 g (5.8 mmol, 34% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.85 (m, 2H), 7.81 – 7.73 (m, 2H), 6.06 (t, J = 7.7 Hz, 1H), 
4.02 (t, J = 6.5 Hz, 2H), 2.64 – 2.46 (m, 2H), 1.66 – 1.57 (m, 2H), 1.57 – 1.30 (m, 4H), 1.16 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 178.7, 166.5, 134.8, 131.7, 124.0, 64.2, 64.1, 38.8, 36.1, 28.5, 27.3, 
26.4, 25.2. 
FT-IR (film): 3496, 2920, 2354, 1726, 1461, 1362, 1148, 1049, 883, 738 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C19H24NO4: 330.2, found: 330.2. 
 
 
Methyl 6-chloro-6-(1,3-dioxoisoindolin-2-yl)hexanoate.  The title compound was 
synthesized according to GP-1 from methyl 6,6-dimethoxyhexanoate (3.60 g, 18.9 mmol).  The 
product was purified by column chromatography on acidic Al2O3 (1:4 EtOAc/hexanes).  1.4 g 
(4.5 mmol, 24% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.96 – 7.85 (m, 2H), 7.83 – 7.69 (m, 2H), 6.06 (t, J = 7.6 Hz, 1H), 
3.64 (s, 3H), 2.55 (q, J = 7.7 Hz, 2H), 2.31 (t, J = 7.4 Hz, 2H), 1.74 – 1.61 (m, 2H), 1.59 – 1.45 (m, 
1H), 1.44 – 1.31 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 173.8, 166.4, 134.8, 131.7, 124.0, 64.0, 51.7, 35.8, 33.8, 26.2, 24.0. 
FT-IR (film): 3494, 2950, 2356, 1731, 1360, 1214, 1052, 879, 728 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C15H16NO4: 274.1, found: 274.1. 
 
 
6-Chloro-6-(1,3-dioxoisoindolin-2-yl)hexyl ethyl carbonate.  The title compound was 
synthesized according to GP-1 from 6,6-dimethoxyhexyl ethyl carbonate (4.68 g, 20.0 mmol).  
The product was purified by column chromatography on acidic Al2O3 (1:3 EtOAc/hexanes).  
2.63 g (7.45 mmol, 37% yield over 2 steps).  Yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.95 – 7.83 (m, 2H), 7.83 – 7.70 (m, 2H), 6.05 (t, J = 7.6 Hz, 1H), 
4.16 (q, J = 7.1 Hz, 2H), 4.10 (t, J = 6.5 Hz, 2H), 2.64 – 2.46 (m, 2H), 1.73 – 1.60 (m, 2H), 1.59 – 1.33 
(m, 4H), 1.29 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.4, 155.3, 134.8, 131.7, 124.0, 67.6, 64.1, 64.0, 36.0, 28.5, 26.3, 
25.0, 14.4. 
FT-IR (film): 3499, 2912, 2354, 1728, 1358, 1011, 879, 729 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C17H20NO5: 318.1, found: 318.1. 
 
 
2-(1-Chloro-3-fluoropropyl)isoindoline-1,3-dione.  The title compound was synthesized 
according to GP-1 from 3-fluoro-1,1-dimethoxypropane (1.22 g, 10.0 mmol).  The product was 
purified by recrystallization.  0.54 g (2.2 mmol, 22% yield over 2 steps).  White solid. 
S–12 
1H NMR (400 MHz, CDCl3) δ 7.99 – 7.86 (m, 2H), 7.86 – 7.72 (m, 2H), 6.32 (dd, J = 8.5, 6.2 
Hz, 1H), 4.80 – 4.44 (m, 2H), 3.11 – 2.75 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 166.4, 134.9, 131.7, 124.1, 80.3 (d, J = 168 Hz), 60.8 (d, J = 5.1 
Hz), 37.0 (d, J = 19.2 Hz). 
19F NMR (376 MHz, CDCl3) δ –220.8. 
FT-IR (film): 3493, 2972, 2353, 1731, 1470, 1360, 1058, 901, 721 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C11H9FNO2: 206.1, found: 206.1. 
 
 
2-(1,4-Dichlorobutyl)isoindoline-1,3-dione.  The title compound was synthesized 
according to GP-1 from 4-chloro-1,1-dimethoxybutane (3.04 g, 20.0 mmol).  The product was 
purified by recrystallization.  2.66 g (9.82 mmol, 49% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.98 – 7.84 (m, 2H), 7.84 – 7.71 (m, 2H), 6.09 (t, J = 7.6 Hz, 1H), 
3.69 – 3.48 (m, 2H), 2.84 – 2.59 (m, 2H), 2.09 – 1.93 (m, 1H), 1.93 – 1.77 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 166.4, 134.9, 131.6, 124.1, 63.5, 43.7, 33.5, 29.7. 
FT-IR (film): 3486, 2964, 2358, 1731, 1372, 1106, 883, 720 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C12H11ClNO2: 236.0, found: 236.1. 
 
 
2-(6-Bromo-1-chlorohexyl)isoindoline-1,3-dione.  The title compound was synthesized 
according to GP-1 from 6-bromo-1,1-dimethoxyhexane (4.48 g, 20.0 mmol).  The product was 
purified by recrystallization.  2.5 g (7.3 mmol, 36% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.98 – 7.86 (m, 2H), 7.86 – 7.70 (m, 2H), 6.07 (t, J = 7.7 Hz, 1H), 
3.38 (t, J = 6.7 Hz, 2H), 2.66 – 2.46 (m, 2H), 1.95 – 1.77 (m, 2H), 1.57 – 1.44 (m, 3H), 1.44 – 1.30 
(m, 1H). 
13C NMR (101 MHz, CDCl3) δ 166.5, 134.8, 131.7, 124.0, 64.1, 35.9, 33.5, 32.5, 27.3, 25.9. 
FT-IR (film): 3490, 2936, 2354, 1728, 1358, 1038, 878, 720 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C14H15BrNO2: 308.0, found: 308.0. 
 
 
2-(1-Chloro-6-(3-chloro-1H-indazol-1-yl)hexyl)isoindoline-1,3-dione.  The title 
compound was synthesized according to GP-2 from 2-(6-bromo-1-methoxyhexyl)isoindoline-
1,3-dione (2.37 g, 6.99 mmol) and 3-chloro-1H-indazole (1.39 g, 9.14 mmol).  The product was 
purified by recrystallization.  1.7 g (4.1 mmol, 59% yield over 2 steps).  Yellow solid. 
S–13 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.83 (m, 2H), 7.82 – 7.72 (m, 2H), 7.69 – 7.60 (m, 1H), 
7.45 – 7.31 (m, 2H), 7.22 – 7.13 (m, 1H), 6.03 (t, J = 7.7 Hz, 1H), 4.30 (t, J = 7.0 Hz, 2H), 2.64 – 2.40 
(m, 2H), 2.04 – 1.83 (m, 2H), 1.55 – 1.43 (m, 1H), 1.44 – 1.28 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 166.3, 140.8, 134.7, 132.6, 131.5, 127.4, 123.9, 121.1, 121.0, 119.9, 
109.2, 63.9, 48.9, 35.8, 29.5, 26.2, 25.9. 
FT-IR (film): 3492, 2936, 2354, 1731, 1469, 1360, 1046, 879, 746 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C21H19ClN3O2: 380.1, found: 380.1. 
 
 
6-Chloro-6-(1,3-dioxoisoindolin-2-yl)hexyl (2S)-2-(4-isobutylphenyl)propanoate.  The 
title compound was synthesized according to GP-2 from 2-(6-bromo-1-
methoxyhexyl)isoindoline-1,3-dione (2.37 g, 6.99 mmol) and (S)-2-(4-isobutylphenyl)propanoic 
acid (1.87 g, 9.08 mmol).  The product was purified by column chromatography on acidic 
Al2O3 (1:4 EtOAc/hexanes).  1.4 g (3.0 mmol, 43% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.95 – 7.85 (m, 2H), 7.82 – 7.73 (m, 2H), 7.22 – 7.15 (m, 2H), 
7.12 – 7.05 (m, 2H), 6.03 (t, J = 7.7 Hz, 1H), 4.03 (t, J = 5.9 Hz, 2H), 3.67 (q, J = 7.2 Hz, 1H), 2.56 – 
2.39 (m, 4H), 1.92 – 1.74 (m, 1H), 1.64 – 1.51 (m, 2H), 1.51 – 1.37 (m, 4H), 1.38 – 1.23 (m, 3H), 
0.87 (d, J = 6.8 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 174.9, 166.5, 140.6, 138.0, 134.8, 131.7, 129.4, 127.3, 124.0, 64.42, 
64.40, 64.1, 45.3, 45.1, 36.0, 30.3, 28.4, 26.3, 25.0, 22.5, 18.5. 
FT-IR (film): 3494, 2915, 2355, 1728, 1359, 1029, 727, 681 cm-1. 
LC-MS (ESI-MS) m/z [M-Cl]+ calcd for C27H32NO4: 434.2, found: 434.2. 
 
 
1,3-Dioxoisoindolin-2-yl (tert-butoxycarbonyl)alaninate.  The title compound was 
synthesized according to GP-3 from (tert-butoxycarbonyl)alanine (1.91 g, 10.1 mmol).  1.28 g 
(3.83 mmol, 38% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.85 (m, 2H), 7.85 – 7.75 (m, 2H), 5.23 – 4.98 (m, 1H), 
4.86 – 4.44 (m, 1H), 1.63 (d, J = 7.2 Hz, 3H), 1.56 – 1.40 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 170.1, 161.6, 154.9, 134.8, 128.9, 124.0, 80.7, 47.9, 28.4, 19.1. 
FT-IR (film): 3356, 2978, 1749, 1368, 1162, 1050, 878, 753, 698 cm-1. 




1,3-Dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)butanoate.  The title compound 
was synthesized according to GP-3 from 2-((tert-butoxycarbonyl)amino)butanoic acid (5.00 g, 
24.6 mmol).  1.76 g (5.06 mmol, 21% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.89 (m, 2H), 7.85 – 7.75 (m, 2H), 5.05 (d, J = 8.7 Hz, 1H), 4.75 – 
4.68 (m, 1H), 2.00 (m, 2H), 1.49 (s, 9H), 1.24 – 1.07 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.5, 161.6, 155.0, 135.0, 129.0, 124.1, 80.6, 53.2, 28.4, 26.5, 9.4. 
FT-IR (film): 3370, 2976, 1789, 1747, 1367, 1167, 1063, 877, 682 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C17H20N2NaO6: 371.1, found: 371.1. 
 
 
1,3-Dioxoisoindolin-2-yl (tert-butoxycarbonyl)leucinate.  The title compound was 
synthesized according to GP-3 from (tert-butoxycarbonyl)leucine (5.00 g, 21.6 mmol).  5.63 g 
(15.0 mmol, 69% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.84 (m, 2H), 7.84 – 7.74 (m, 2H), 4.93 (d, J = 8.9 Hz, 1H), 
4.83 – 4.66 (m, 1H), 1.95 – 1.81 (m, 2H), 1.77 – 1.65 (m, 1H), 1.50 (s, 9H), 1.05 – 0.99 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 170.0, 161.6, 155.0, 134.9, 128.9, 124.1, 80.6, 50.7, 41.9, 28.4, 
24.8, 22.9, 21.9. 
FT-IR (film): 3386, 2962, 1747, 1367, 1166, 1081, 968, 698 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C19H24N2NaO6: 399.2, found 399.1. 
 
 
1,3-Dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetate.  The title 
compound was synthesized according to GP-3 from 2-((tert-butoxycarbonyl)amino)-2-
cyclohexylacetic acid (6.00 g, 23.3 mmol).  6.78 g (16.8 mmol, 72% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.83 (m, 2H), 7.83 – 7.74 (m, 2H), 5.05 (d, J = 9.4 Hz, 1H), 
4.68 – 4.60 (m, 1H), 2.05 – 1.92 (m, 1H), 1.90 – 1.78 (m, 4H), 1.74 – 1.65 (m, 1H), 1.47 (s, 9H), 1.40 
– 1.11 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 161.7, 155.2, 134.9, 129.0, 124.1, 80.5, 56.9, 41.4, 29.2, 
28.4, 26.0. 
FT-IR (film): 3275, 2932, 1747, 1366, 1162, 972, 877, 754, 697 cm-1. 




1,3-Dioxoisoindolin-2-yl (tert-butoxycarbonyl)valinate.  The title compound was 
synthesized according to GP-3 from (tert-butoxycarbonyl)valine (4.50 g, 20.7 mmol).  2.79 g 
(7.71 mmol, 37% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.84 (m, 2H), 7.84 – 7.74 (m, 2H), 5.05 (d, J = 9.4 Hz, 1H), 
4.70 – 4.62 (m, 1H), 2.42 – 2.28 (m, 1H), 1.47 (s, 9H), 1.17 – 1.05 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 161.7, 155.3, 134.9, 129.0, 124.1, 80.5, 57.2, 31.9, 28.4, 
18.9, 17.5. 
FT-IR (film): 3369, 2974, 1743, 1366, 1166, 1072, 970, 759, 697 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C18H22N2NaO6: 385.1, found: 385.1. 
 
 
1,3-Dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate.  The title 
compound was synthesized according to GP-3 from 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoic acid (3.00 g, 10.7 mmol).  3.08 g (7.26 mmol, 68% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.95 – 7.86 (m, 2H), 7.85 – 7.76 (m, 2H), 7.36 – 7.18 (m, 5H), 
5.07 (d, J = 8.7 Hz, 1H), 4.85 – 4.75 (m, 1H), 2.89 – 2.78 (m, 2H), 2.42 – 2.11 (m, 2H), 1.48 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 169.5, 161.6, 154.9, 140.5, 135.0, 129.0, 128.73, 128.65, 126.4, 
124.2, 80.7, 51.9, 34.9, 31.4, 28.4. 
FT-IR (film): 3374, 2976, 1789, 1746, 1368, 1166, 759, 697 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C23H24N2NaO6: 447.2, found: 447.1. 
 
 
1,3-Dioxoisoindolin-2-yl (tert-butoxycarbonyl)phenylalaninate.  The title compound 
was synthesized according to GP-3 from (tert-butoxycarbonyl)phenylalanine (4.50 g, 17.0 
mmol).  3.59 g (8.76 mmol, 52% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.95 – 7.85 (m, 2H), 7.84 – 7.75 (m, 2H), 7.43 – 7.25 (m, 5H), 
5.10 – 4.58 (m, 2H), 3.42 – 3.12 (m, 2H), 1.43 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 168.7, 161.5, 154.7, 135.0, 129.8, 129.7, 128.9, 128.8, 127.4, 124.1, 
80.6, 52.8, 38.3, 28.3. 
FT-IR (film): 3349, 2977, 1747, 1710, 1514, 1366, 1172, 753, 698 cm-1. 




1,3-Dioxoisoindolin-2-yl N2,N6-bis(tert-butoxycarbonyl)lysinate.  The title compound 
was synthesized according to GP-3 from N2,N6-bis(tert-butoxycarbonyl)lysine (5.49 g, 15.9 
mmol).  1.07 g (2.18 mmol, 14% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.90 – 7.86 (m, 2H), 7.82 – 7.78 (m, 2H), 5.22 – 4.86 (m, 1H), 
4.68 – 4.44 (m, 2H), 3.22 – 3.12 (m, 2H), 2.05 – 1.87 (m, 2H), 1.57 – 1.41 (m, 22H). 
13C NMR (101 MHz, CDCl3) δ 169.6, 161.7, 156.3, 155.1, 135.0, 129.0, 124.2, 80.7, 79.3, 52.0, 
40.0, 32.4, 29.6, 28.6, 28.4, 22.1. 
FT-IR (film): 3356, 2977, 1747, 1709, 1518, 1366, 1174, 759, 697 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C24H33N3NaO8: 514.2, found: 514.2. 
 
 
1,3-Dioxoisoindolin-2-yl (tert-butoxycarbonyl)methioninate.  The title compound was 
synthesized according to GP-3 from (tert-butoxycarbonyl)methionine (5.35 g, 21.5 mmol).  
4.87 g (12.4 mmol, 58% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.84 (m, 2H), 7.84 – 7.75 (m, 2H), 5.23 – 5.04 (m, 1H), 
4.94 – 4.61 (m, 1H), 2.77 – 2.62 (m, 2H), 2.36 – 2.12 (m, 5H), 1.46 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 169.2, 161.5, 154.9, 135.0, 128.9, 124.1, 80.7, 51.4, 32.4, 29.6, 
28.3, 15.5. 
FT-IR (film): 3370, 2978, 1747, 1367, 1186, 968, 758, 698 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C18H22N2NaO6S: 417.1, found 417.1. 
 
 
1,3-Dioxoisoindolin-2-yl Nα-(tert-butoxycarbonyl)-1-methyltryptophanate.  The title 
compound was synthesized according to GP-3 from Nα-(tert-butoxycarbonyl)-1-
methyltryptophan (2.2 g, 6.9 mmol).  1.2 g (2.5 mmol, 37% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.95 – 7.88 (m, 2H), 7.84 – 7.77 (m, 2H), 7.67 – 7.58 (m, 1H), 
7.35 – 7.27 (m, 2H), 7.27 – 7.09 (m, 2H), 5.20 – 4.59 (m, 2H), 3.80 (s, 3H), 3.62 – 3.29 (m, 2H), 1.44 
(s, 9H). 
13C NMR (101 MHz, CDCl3) δ 168.9, 161.7, 154.9, 137.0, 134.9, 129.0, 128.7, 124.2, 121.8, 119.4, 
118.9, 109.4, 107.0, 80.4, 53.5, 32.9, 28.4, 28.1, 27.9. 
FT-IR (film): 3380, 2978, 1731, 1486, 1371, 1166, 972, 754, 697 cm-1. 
S–17 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C25H25N3NaO6: 486.2, found: 486.2. 
 
 
1,3-Dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-3-(thiophen-2-yl)propanoate.  
The title compound was synthesized according to GP-3 from 2-((tert-butoxycarbonyl)amino)-
3-(thiophen-2-yl)propanoic acid (4.00 g, 14.7 mmol).  3.28 g (7.88 mmol, 54% yield).  Light-
yellow solid. 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.89 (m, 2H), 7.82 – 7.79 (m, 2H), 7.26 – 7.19 (m, 1H), 
7.11 – 7.06 (m, 1H), 7.00 (dd, J = 5.2, 3.5 Hz, 1H), 5.15 – 4.69 (m, 2H), 3.62 – 3.51 (m, 2H), 1.47 (s, 
9H). 
13C NMR (101 MHz, CDCl3) δ 168.3, 161.5, 154.7, 136.1, 135.0, 134.0, 128.9, 127.8, 127.5, 125.3, 
124.2, 123.2, 80.8, 52.9, 32.5, 28.4. 
FT-IR (film): 3369, 2978, 1746, 1720, 1368, 1162, 970, 758, 697 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C20H20N2NaO6S: 439.1, found: 439.1. 
 
 
1-(1,3-Dioxoisoindolin-2-yl) 5-methyl (tert-butoxycarbonyl)glutamate.  The title 
compound was synthesized according to GP-3 from 2-((tert-butoxycarbonyl)amino)-5-
methoxy-5-oxopentanoic acid (0.68 g, 2.6 mmol).  0.53 g (1.3 mmol, 51% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.86 (m, 2H), 7.86 – 7.76 (m, 2H), 5.28 – 5.04 (m, 1H), 
4.89 – 4.49 (m, 1H), 3.72 (s, 3H), 2.60 (t, J = 7.7 Hz, 2H), 2.40 – 2.24 (m, 2H), 1.46 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 173.1, 169.1, 161.6, 155.0, 135.0, 128.9, 124.2, 80.8, 52.1, 51.6, 
29.8, 28.4, 28.0. 
FT-IR (film): 3368, 2978, 1789, 1746, 1368, 1164, 878, 697 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C19H22N2NaO8: 429.1, found: 429.1. 
 
 
1-(tert-Butyl) 2-(1,3-dioxoisoindolin-2-yl) pyrrolidine-1,2-dicarboxylate.  The title 
compound was synthesized according to GP-3 from (tert-butoxycarbonyl)proline (3.00 g, 13.9 
mmol).  1.41 g (3.92 mmol, 28% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.83 (m, 2H), 7.83 – 7.73 (m, 2H), 4.65 – 4.57 (m, 1H), 
3.69 – 3.37 (m, 2H), 2.51 – 2.30 (m, 2H), 2.13 – 1.92 (m, 2H), 1.51 (s, 9H). 
S–18 
13C NMR (101 MHz, CDCl3) δ 169.7, 161.8, 153.5, 134.9, 128.9, 124.0, 81.2, 57.3, 46.3, 31.5, 
28.2, 23.6. 
FT-IR (film): 2977, 1745, 1394, 1163, 1069, 972, 757, 697 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C18H20N2NaO6: 383.1, found: 383.1. 
 
 
1,3-Dioxoisoindolin-2-yl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)butanoate.  The 
title compound was synthesized according to GP-3 from 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)butanoic acid (5.00 g, 15.4 mmol).  4.60 g (9.79 mmol, 64% yield).  
White solid. 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.85 (m, 2H), 7.85 – 7.72 (m, 4H), 7.64 – 7.57 (m, 2H), 
7.43 – 7.37 (m, 2H), 7.36 – 7.29 (m, 2H), 5.32 (d, J = 8.6 Hz, 1H), 4.84 – 4.59 (m, 1H), 4.52 – 4.43 
(m, 2H), 4.25 (t, J = 7.0 Hz, 1H), 2.21 – 1.89 (m, 2H), 1.12 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.2, 161.6, 155.7, 143.9, 143.7, 141.4, 135.0, 128.9, 127.8, 127.2, 
125.2, 124.2, 120.1, 67.4, 53.6, 47.2, 26.3, 9.4. 
FT-IR (film): 3340, 2974, 1789, 1745, 1518, 1186, 1065, 758, 696 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C27H22N2NaO6: 493.1, found: 493.1. 
 
 
1,3-Dioxoisoindolin-2-yl 2-(((benzyloxy)carbonyl)amino)butanoate.  The title compound 
was synthesized according to GP-3 from 2-(((benzyloxy)carbonyl)amino)butanoic acid (3.60 g, 
15.2 mmol).  2.46 g (6.44 mmol, 42% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.94 – 7.86 (m, 2H), 7.86 – 7.75 (m, 2H), 7.40 – 7.28 (m, 5H), 
5.34 – 5.27 (m, 1H), 5.21 – 5.09 (m, 2H), 4.86 – 4.54 (m, 1H), 2.19 – 1.90 (m, 2H), 1.11 (t, J = 7.5 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.2, 161.6, 155.7, 136.1, 135.0, 128.9, 128.7, 128.4, 128.3, 124.2, 
67.5, 53.5, 26.4, 9.3. 
FT-IR (film): 3328, 1788, 1745, 1186, 1065, 877, 696 cm-1. 




IV.  Preparation of Nucleophiles 
 
 
General Procedure 4 (GP-4): Preparation of organozinc reagents.  In the air, an oven-
dried 100 mL Schlenk tube was charged with a stir bar and zinc powder (1.5 equiv, ~100 mesh, 
Alfa, 99.9%), and then it was sealed with a rubber septum cap.  The tube was placed under a 
nitrogen atmosphere by evacuating and back-filling the tube (three cycles).  Then, the tube 
was heated with a heat gun (~250 °C) under vacuum (~1 torr) for 10 min.  The Schlenk tube 
was allowed to cool to room temperature, and it was back-filled with nitrogen.  THF (0.5 
mL/mmol of the alkyl iodide) was added via syringe.  The cap was removed, and iodine 
(0.050 equiv) was added in one portion under a positive flow of nitrogen (the cap was then 
replaced), leading initially to a red color that faded after ~5 sec of vigorous stirring (1000 rpm).  
A solution of the alkyl iodide (1.0 equiv) in THF (0.5 mL/mmol of the alkyl iodide), prepared 
in a 20 mL vial equipped with a nitrogen balloon, was added via syringe in one portion to the 
gray suspension of zinc powder.  Then, the Schlenk tube was capped tightly under a nitrogen 
atmosphere and transferred to an oil bath.  The reaction mixture was stirred vigorously at 50 
°C for 12 h (the disappearance of the alkyl iodide and the formation of the alkylzinc reagent 
can readily be monitored via GC analysis of the quenched alkylzinc reagent).  After the alkyl 
iodide had been consumed, the gray mixture was filtered through a syringe filter (PTFE, 0.45 
μM) to afford a colorless to slightly yellow solution.  The alkylzinc solution was titrated by 
the method of Knochel, using iodine in THF.4  The concentration of the alkylzinc reagents 












V.  Catalytic Enantioconvergent Cross-Couplings 
 
 
General Procedure 5 (GP-5): Alkyl chlorides as the electrophile. 
Preparation of a solution of the catalyst: In the air, NiBr2⋅glyme (18.4 mg, 0.060 mmol, 10 
mol%) and (S,S)-L1 (65.2 mg, 0.072 mmol, 12 mol%) were added to an oven-dried 40 mL vial 
equipped with a cross-type stir bar.  The vial was closed with a PTFE septum cap, the joint 
was wrapped with electric tape, and the vial was placed under a nitrogen atmosphere by 
evacuating and back-filling the vial (three cycles).  A balloon filled with nitrogen was 
attached to the vial.  THF (6.0 mL) was added to the vial, and the mixture was stirred at room 
temperature for 30 min, leading to an orange, homogeneous solution. 
Cross-coupling: In the air, an oven-dried 8 mL vial was charged with the racemic alkyl 
chloride (0.60 mmol, 1.0 equiv).  The vial was closed with a PTFE septum cap, and then it was 
evacuated and back-filled with nitrogen (three cycles).  THF (3.0 mL) was added, and the 
resulting solution was transferred via syringe to the 40 mL reaction vial.  The 8 mL vial was 
rinsed with THF (3.0 mL), and the washing was transferred to the reaction vial.  The reaction 
vial was then placed in an i-PrOH cooling bath at 0 °C, and the reaction mixture was stirred at 
0 °C for 10 min.  Then, the alkylzinc solution (0.66 mmol, 1.1 equiv) was added dropwise via 
syringe over 3 min, during which the reaction mixture turned dark.  The balloon was 
removed, and the septum cap was sealed with grease.  The mixture was stirred at 0 °C for 36 
h. 
Work-up: The reaction was quenched with methanol (0.2 mL), and the mixture was passed 
through a plug of silica gel; the vial, the cap, and the silica gel were rinsed with Et2O.  The 




General Procedure 6 (GP-6): NHP esters as the electrophile. 
Preparation of a solution of the catalyst: In the air, NiBr2glyme (9.3 mg, 0.030 mmol, 5.0 
mol%), (R,R)-L2 (10.7 mg, 0.036 mmol, 6.0 mol%), and anhydrous LiCl (52.1 mg, 1.2 mmol, 2.0 



















mL vial in a glovebox, transfer the vial out of the glovebox, and pour the compound into the 
reaction vial) were added sequentially to an oven-dried 40 mL vial equipped with a cross-type 
stir bar.  The vial was then capped with a PTFE septum cap and wrapped with electrical tape.  
The reaction vial was evacuated and back-filled with nitrogen (four cycles), after which a 
nitrogen-filled balloon was attached.  THF (4.5 mL) was added via syringe, and the mixture 
was allowed to stir for 30 min, during which it became a light-green, homogeneous solution. 
Cross-coupling: In the air, an oven-dried 8 mL vial was charged with DMAP (36.7 mg, 0.30 
mmol, 0.50 equiv) and the NHP ester (0.60 mmol, 1.0 equiv).  The vial was closed with a PTFE 
septum cap, and then it was evacuated and back-filled with nitrogen (three cycles).  THF (3.0 
mL) was added, and the resulting solution was transferred via syringe to the 40 mL reaction 
vial, leading to an orange, opaque mixture.  The 8 mL vial was rinsed with THF (0.5 mL), 
which was also added to the reaction vial.  Next, TMSCl (61 µL, 0.48 mmol, 0.80 equiv) was 
added via microsyringe, leading to a colorless, opaque mixture.  The reaction vial was then 
placed in an i-PrOH cooling bath at 0 °C, and the mixture was stirred at 0 °C for 10 min.  
Then, the alkylzinc solution (0.72 mmol, 1.2 equiv) was added dropwise via syringe over 5 
min, during which the reaction mixture became yellow and homogeneous.  The balloon was 
removed and the septum cap was sealed with grease.  The mixture was stirred at 0 °C for 18 
h. 
Work-up: The reaction was quenched with methanol (0.2 mL), and the mixture was passed 
through a plug of silica gel; the vial, the cap, and the silica gel were rinsed with Et2O.  The 
filtrate was concentrated, and the residue was purified by column chromatography on silica 
gel. 
 
General Procedure 7 (GP-7): α-branched NHP esters as the electrophile. 
Preparation of a solution of the catalyst: In the air, NiBr2glyme (18.6 mg, 0.060 mmol, 10 
mol%), (R,R)-L2 (21.4 mg, 0.072 mmol, 12 mol%), and anhydrous LiCl (130 mg, 3.0 mmol, 5.0 
equiv; because LiCl is hygroscopic, it is recommended to weigh the compound in a capped 4 
mL vial in a glovebox, transfer the vial out of the glovebox, and pour the compound into the 
reaction vial) were added sequentially to an oven-dried 40 mL vial equipped with a cross-type 
stir bar.  The vial was then capped with a PTFE septum cap and wrapped with electrical tape.  
The reaction vial was evacuated and back-filled with nitrogen (four cycles), after which a 
nitrogen-filled balloon was attached.  THF (4.5 mL) was added via syringe, and the mixture 
was allowed to stir for 30 min, during which it became a light-green, homogeneous solution. 
Cross-coupling: In the air, an oven-dried 8 mL vial was charged with the NHP ester (0.60 
mmol, 1.0 equiv).  The vial was closed with a PTFE septum cap, and then it was evacuated 
and back-filled with nitrogen (three cycles).  THF (3.0 mL) was added, and the resulting 
solution was transferred via syringe to the 40 mL reaction vial, leading to an orange, 
homogeneous solution.  The 8 mL vial was rinsed with THF (0.5 mL), which was also added 
to the reaction vial.  The reaction vial was then placed in an i-PrOH cooling bath at 0 °C, and 
the mixture was stirred at 0 °C for 10 min.  Then, the alkylzinc solution (0.72 mmol, 1.2 equiv) 
was added dropwise via syringe over 5 min, during which the reaction mixture became light-
S–23 
red and homogeneous.  The balloon was removed, and the septum cap was sealed with 
grease.  The mixture was stirred at 0 °C for 18 h. 
Work-up: The reaction was quenched with methanol (0.2 mL), and the mixture was passed 
through a plug of silica gel; the vial, the cap, and the silica gel were rinsed with Et2O.  The 




2-(4-Cyclohexylbutan-2-yl)isoindoline-1,3-dione (1).  The title compound was 
synthesized according to GP-5 from 2-(1-chloroethyl)isoindoline-1,3-dione and Zn-1.  The 
product was purified by column chromatography on silica gel (1:10 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L1: 159 mg, 93% yield, 88% ee; (R,R)-L1: 164 mg, 96% yield, 88% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 3.9 
min (minor), 4.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.77 (m, 2H), 7.73 – 7.66 (m, 2H), 4.35 – 4.23 (m, 1H), 
2.12 – 1.97 (m, 1H), 1.82 – 1.69 (m, 1H), 1.68 – 1.55 (m, 5H), 1.45 (d, J = 6.9 Hz, 3H), 1.29 – 0.99 
(m, 6H), 0.91 – 0.73 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.7, 133.9, 132.2, 123.2, 48.0, 37.6, 34.6, 33.5, 33.3, 31.3, 26.7, 
26.5, 26.4, 18.9. 
FT-IR (film): 3470, 2920, 2353, 1697, 1367, 1022, 869, 728 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H24NO2: 286.1802, found: 286.1806. 
[]22D = −13.3 (c 1.0, CHCl3); 88% ee, from (S,S)-L1. 
 
 
2-(1-Cyclohexylpentan-3-yl)isoindoline-1,3-dione (2).  The title compound was 
synthesized according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-1.  The 
product was purified by column chromatography on silica gel (1:15 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L1: 167 mg, 93% yield, 92% ee; (R,R)-L1: 171 mg, 95% yield, 92% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 3.8 
min (minor), 4.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H), 7.73 – 7.67 (m, 2H), 4.12 – 4.01 (m, 1H), 
2.13 – 1.97 (m, 2H), 1.84 – 1.68 (m, 2H), 1.68 – 1.55 (m, 5H), 1.26 – 0.99 (m, 6H), 0.85 (t, J = 7.6 
Hz, 3H), 0.87 – 0.72 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 123.2, 54.5, 37.6, 34.5, 33.6, 33.3, 29.7, 26.7, 
26.5, 26.4, 25.7, 11.3. 
S–24 
FT-IR (film): 3466, 2916, 2353, 1697, 1362, 1050, 727 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H26NO2: 300.1958, found: 300.1962. 
[]22D = −5.2 (c 1.0, CHCl3); 92% ee, from (S,S)-L1. 
Gram-scale reaction: In the air, NiBr2⋅glyme (153 mg, 0.50 mmol, 0.10 equiv) and (S,S)-L1 
(543 mg, 0.60 mmol, 0.12 equiv) were added to an oven-dried 250 mL round-bottom flask 
equipped with a stir bar.  The flask was closed with a rubber septum cap, the joint was 
wrapped with electrical tape, and the flask was placed under a nitrogen atmosphere by 
evacuating and back-filling the flask (three cycles).  A balloon filled with nitrogen was 
attached to the reaction flask.  THF (40 mL) was added to the flask, and the mixture was 
stirred at room temperature for 30 min, at which time it was an orange, homogeneous 
solution.  In the air, an oven-dried 40 mL vial was charged with 2-(1-
chloropropyl)isoindoline-1,3-dione (1.12 g, 5.0 mmol, 1.0 equiv).  The vial was capped with a 
PTFE septum cap, and then it was evacuated and back-filled with nitrogen (three cycles).  
THF (30 mL) was added to the vial to dissolve the electrophile.  Next, this solution of the 
electrophile was added in one portion via syringe to the catalyst solution.  The 40 mL vial was 
rinsed with THF (30 mL), and the washing was transferred to the reaction flask.  The reaction 
flask was then placed in an i-PrOH cooling bath at 0 °C, and the reaction mixture was stirred at 
0 °C for 10 min.  Then, Zn-1 (5.5 mmol, 1.1 equiv) was added dropwise via syringe over 10 
min, during which the reaction mixture turned dark.  The balloon was removed, and the 
septum was sealed with electrical tape.  The reaction mixture was stirred at 0 °C for 36 h.  
The reaction was quenched at 0 °C by the addition of MeOH (1.0 mL).  Next, the reaction 
mixture was passed through a column of silica gel (5 cm), and the flask, the septum, and the 
silica gel were rinsed with Et2O.  The filtrate was concentrated, and the residue was purified 
by column chromatography on silica gel (1:15 Et2O/hexanes).  Colorless oil. 
(S,S)-L1: 1.40 g, 93% yield, 92% ee. 
 
 
2-(1-Cyclohexylheptan-3-yl)isoindoline-1,3-dione (3).  The title compound was 
synthesized according to GP-5 from 2-(1-chloropentyl)isoindoline-1,3-dione and Zn-1.  The 
product was purified by column chromatography on silica gel (1:15 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L1: 189 mg, 96% yield, 91% ee; (R,R)-L1: 183 mg, 93% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2% i-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (S,S)-L1: 10.4 
min (minor), 11.3 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H), 7.74 – 7.67 (m, 2H), 4.19 – 4.08 (m, 1H), 
2.13 – 1.98 (m, 2H), 1.78 – 1.54 (m, 7H), 1.40 – 0.98 (m, 10H), 0.91 – 0.72 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 123.2, 52.8, 37.6, 34.5, 33.6, 33.3, 32.4, 30.0, 
29.0, 26.8, 26.5, 26.4, 22.5, 14.1. 
FT-IR (film): 3466, 2919, 2354, 1699, 1371, 1050, 876, 726 cm-1. 
S–25 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H30NO2: 328.2271, found: 328.2268. 
[]22D = −1.7 (c 1.0, CHCl3); 91% ee, from (S,S)-L1. 
 
 
2-(1-Cyclohexyl-5-methylhexan-3-yl)isoindoline-1,3-dione (4).  The title compound was 
synthesized according to GP-5 from 2-(1-chloro-3-methylbutyl)isoindoline-1,3-dione and Zn-1.  
The product was purified by column chromatography on silica gel (1:12 Et2O/hexanes).  
Colorless oil. 
(S,S)-L1: 175 mg, 89% yield, 81% ee; (R,R)-L1: 176 mg, 90% yield, 81% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IE-3 column (3% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 4.7 
min (minor), 4.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.87 – 7.75 (m, 2H), 7.75 – 7.64 (m, 2H), 4.33 – 4.16 (m, 1H), 
2.25 – 1.94 (m, 2H), 1.75 – 1.55 (m, 6H), 1.50 – 1.36 (m, 2H), 1.27 – 0.98 (m, 6H), 0.96 – 0.73 (m, 
8H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 123.2, 50.8, 41.6, 37.7, 34.5, 33.5, 33.3, 30.4, 
26.8, 26.5, 26.4, 25.4, 23.4, 22.0. 
FT-IR (film): 3464, 2919, 2354, 1709, 1372, 1168, 1072, 871, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H30NO2: 328.2271, found: 328.2269. 
[]22D = −2.8 (c 1.0, CHCl3); 81% ee, from (S,S)-L1. 
 
 
2-(1-Cyclohexyl-5-phenylpentan-3-yl)isoindoline-1,3-dione (5).  The title compound was 
synthesized according to GP-5 from 2-(1-chloro-3-phenylpropyl)isoindoline-1,3-dione and Zn-
1.  The product was purified by column chromatography on silica gel (1:15 Et2O/hexanes).  
Colorless oil. 
(S,S)-L1: 219 mg, 97% yield, 90% ee; (R,R)-L1: 223 mg, 99% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (10% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 7.1 
min (minor), 7.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.76 (m, 2H), 7.74 – 7.65 (m, 2H), 7.22 – 7.15 (m, 2H), 
7.15 – 7.09 (m, 2H), 7.09 – 7.03 (m, 1H), 4.27 – 4.16 (m, 1H), 2.69 – 2.43 (m, 3H), 2.15 – 1.94 (m, 
2H), 1.82 – 1.69 (m, 1H), 1.69 – 1.54 (m, 5H), 1.25 – 1.01 (m, 6H), 0.91 – 0.72 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.9, 141.4, 133.9, 131.9, 128.4, 125.9, 123.2, 52.7, 37.6, 34.3, 
34.0, 33.5, 33.34, 33.29, 30.1, 26.7, 26.5, 26.4. 
FT-IR (film): 3464, 2920, 2353, 1708, 1378, 1077, 885 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H30NO2: 376.2271, found: 376.2277. 




2-(1-Cyclohexyl-5-(4-(trifluoromethyl)phenyl)pentan-3-yl)isoindoline-1,3-dione (6).  The 
title compound was synthesized according to GP-5 from 2-(1-chloro-3-(4-
(trifluoromethyl)phenyl)propyl)isoindoline-1,3-dione and Zn-1.  The product was purified by 
column chromatography on silica gel (1:12 Et2O/hexanes).  Colorless oil. 
(S,S)-L1: 259 mg, 97% yield, 88% ee; (R,R)-L1: 250 mg, 94% yield, 88% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 7.2 
min (minor), 7.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.79 – 7.72 (m, 2H), 7.71 – 7.63 (m, 2H), 7.37 (d, J = 8.1 Hz, 2H), 
7.21 (d, J = 8.0 Hz, 2H), 4.26 – 4.15 (m, 1H), 2.79 – 2.66 (m, 1H), 2.66 – 2.49 (m, 2H), 2.15 – 1.94 
(m, 2H), 1.82 – 1.68 (m, 1H), 1.68 – 1.53 (m, 5H), 1.23 – 0.97 (m, 6H), 0.90 – 0.70 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 145.4 (q, J = 1.0 Hz), 134.0, 131.8, 128.7, 128.2 (q, J = 32.3 
Hz), 125.2 (q, J = 4.0 Hz), 124.3 (q, J = 273 Hz), 123.1, 52.6, 37.5, 34.3, 33.5, 33.34, 33.29, 33.27, 
30.2, 26.7, 26.43, 26.38. 
19F NMR (282 MHz, CDCl3) δ –62.3. 
FT-IR (film): 3466, 2920, 2354, 1710, 1366, 1120, 1019, 847, 719 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C26H29F3NO2: 444.2145, found: 444.2145. 
[]22D = −13.2 (c 1.0, CHCl3); 88% ee, from (S,S)-L1. 
 
 
2-(1-Cyclohexyl-5-(4-iodophenyl)pentan-3-yl)isoindoline-1,3-dione (7).  The title 
compound was synthesized according to GP-5 from 2-(1-chloro-3-(4-
iodophenyl)propyl)isoindoline-1,3-dione and Zn-1.  The product was purified by column 
chromatography on silica gel (1:15 Et2O/hexanes).  Colorless oil. 
(S,S)-L1: 257 mg, 85% yield, 89% ee; (R,R)-L1: 247 mg, 82% yield, 88% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALCEL OJ-3 column (10% CH3CN 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 5.9 
min (major), 6.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.82 – 7.74 (m, 2H), 7.74 – 7.66 (m, 2H), 7.49 – 7.40 (m, 2H), 
6.90 – 6.81 (m, 2H), 4.24 – 4.11 (m, 1H), 2.67 – 2.42 (m, 3H), 2.15 – 1.89 (m, 2H), 1.78 – 1.58 (m, 
6H), 1.29 – 0.97 (m, 6H), 0.91 – 0.70 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.9, 141.0, 137.4, 134.1, 131.8, 130.5, 123.2, 90.9, 52.6, 37.5, 
34.3, 33.5, 33.4, 33.3, 33.0, 30.2, 26.7, 26.5, 26.4. 
FT-IR (film): 3454, 2915, 2352, 1700, 1358, 1006, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H29INO2: 502.1237, found: 502.1229. 
S–27 
[]22D = −15.2 (c 1.0, CHCl3); 89% ee, from (S,S)-L1. 
 
 
8-Cyclohexyl-6-(1,3-dioxoisoindolin-2-yl)octyl pivalate (8).  The title compound was 
synthesized according to GP-5 from 6-chloro-6-(1,3-dioxoisoindolin-2-yl)hexyl pivalate and 
Zn-1.  The product was purified by column chromatography on silica gel (1:5 Et2O/hexanes).  
Colorless oil. 
(S,S)-L1: 241 mg, 91% yield, 90% ee; (R,R)-L1: 244 mg, 92% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 7.7 
min (minor), 8.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.87 – 7.76 (m, 2H), 7.76 – 7.64 (m, 2H), 4.22 – 4.06 (m, 1H), 
3.99 (t, J = 6.5 Hz, 2H), 2.15 – 1.98 (m, 2H), 1.78 – 1.51 (m, 9H), 1.45 – 0.97 (m, 19H), 0.90 – 0.72 
(m, 2H). 
13C NMR (101 MHz, CDCl3) δ 178.7, 168.9, 134.0, 132.0, 123.3, 64.4, 52.7, 38.8, 37.6, 34.4, 33.5, 
33.3, 32.6, 30.0, 28.7, 27.3, 26.7, 26.52, 26.46, 26.4, 25.9. 
FT-IR (film): 3469, 2918, 2354, 1713, 1370, 1049, 870, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C27H40NO4: 442.2952, found: 442.2960. 
[]22D = +0.7 (c 1.0, CHCl3); 90% ee, from (S,S)-L1. 
 
 
Methyl 8-cyclohexyl-6-(1,3-dioxoisoindolin-2-yl)octanoate (9).  The title compound was 
synthesized according to GP-5 from methyl 6-chloro-6-(1,3-dioxoisoindolin-2-yl)hexanoate 
and Zn-1.  The product was purified by column chromatography on silica gel (1:8 
EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 209 mg, 91% yield, 91% ee; (R,R)-L1: 210 mg, 91% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 11.9 
min (minor), 13.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.79 (m, 2H), 7.74 – 7.67 (m, 2H), 4.19 – 4.09 (m, 1H), 
3.61 (s, 3H), 2.25 (t, J = 7.7 Hz, 2H), 2.16 – 1.98 (m, 2H), 1.78 – 1.57 (m, 9H), 1.36 – 0.98 (m, 8H), 
0.89 – 0.72 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 174.1, 168.9, 134.0, 132.0, 123.3, 52.6, 51.6, 37.6, 34.4, 34.0, 33.6, 
33.3, 32.3, 30.0, 26.7, 26.5, 26.4, 26.3, 24.7. 
FT-IR (film): 3463, 2913, 2355, 1698, 1050, 737 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C23H35N2O4: 403.2591, found: 403.2588. 




8-Cyclohexyl-6-(1,3-dioxoisoindolin-2-yl)octyl ethyl carbonate (10).  The title compound 
was synthesized according to GP-5 from 6-chloro-6-(1,3-dioxoisoindolin-2-yl)hexyl ethyl 
carbonate and Zn-1.  The product was purified by column chromatography on silica gel (1:3 
Et2O/hexanes).  Colorless oil. 
(S,S)-L1: 218 mg, 85% yield, 90% ee; (R,R)-L1: 225 mg, 87% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 8.8 
min (minor), 9.2 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.87 – 7.76 (m, 2H), 7.76 – 7.65 (m, 2H), 4.16 (q, J = 7.2 Hz, 2H), 
4.17 – 4.09 (m, 1H), 4.06 (t, J = 6.6 Hz, 2H), 2.17 – 1.94 (m, 2H), 1.76 – 1.56 (m, 9H), 1.47 – 0.97 
(m, 13H), 0.90 – 0.71 (m, 2H). 
13C NMR (101 MHz, CDCl3) 168.9, 155.4, 134.0, 131.9, 123.3, 67.9, 63.9, 52.7, 37.6, 34.4, 33.5, 
33.3, 32.5, 30.0, 28.7, 26.7, 26.5, 26.44, 26.41, 25.6, 14.4. 
FT-IR (film): 3464, 2920, 2354, 1711, 1168, 1046, 726 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H36NO5: 430.2588, found: 430.2584. 
[]22D = +0.8 (c 1.0, CHCl3); 90% ee, from (S,S)-L1. 
 
 
2-(1-Cyclohexyl-5-fluoropentan-3-yl)isoindoline-1,3-dione (11).  The title compound was 
synthesized according to GP-5 from 2-(1-chloro-3-fluoropropyl)isoindoline-1,3-dione and Zn-
1.  The product was purified by column chromatography on silica gel (1:6 Et2O/hexanes).  
Colorless oil. 
(S,S)-L1: 141 mg, 74% yield, 88% ee; (R,R)-L1: 142 mg, 75% yield, 88% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (10% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 3.7 
min (minor), 4.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.88 – 7.78 (m, 2H), 7.77 – 7.65 (m, 2H), 4.58 – 4.28 (m, 3H), 
2.60 – 2.39 (m, 1H), 2.22 – 2.02 (m, 2H), 1.86 – 1.70 (m, 1H), 1.69 – 1.58 (m, 5H), 1.31 – 0.99 (m, 
6H), 0.93 – 0.70 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 134.1, 131.9, 123.4, 81.7 (d, J = 167 Hz), 49.3 (d, J = 4.0 
Hz), 37.5, 34.2, 33.5, 33.3, 33.2 (d, J = 19.2 Hz), 29.9, 26.7, 26.5, 26.4. 
19F NMR (376 MHz, CDCl3) δ –220.8. 
FT-IR (film): 3469, 2920, 2356, 1713, 1372, 1066, 873, 720 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C19H25FNO2: 318.2, found: 318.2. 





2-(6-Chloro-1-cyclohexylhexan-3-yl)isoindoline-1,3-dione (12).  The title compound was 
synthesized according to GP-5 from 2-(1,4-dichlorobutyl)isoindoline-1,3-dione and Zn-1.  The 
product was purified by column chromatography on silica gel (1:8 Et2O/hexanes).  Colorless 
oil. 
(S,S)-L1: 204 mg, 98% yield, 90% ee; (R,R)-L1: 194 mg, 93% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 8.2 
min (minor), 8.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.91 – 7.78 (m, 2H), 7.78 – 7.65 (m, 2H), 4.26 – 4.09 (m, 1H), 
3.62 – 3.45 (m, 2H), 2.29 – 2.15 (m, 1H), 2.15 – 2.01 (m, 1H), 1.96 – 1.84 (m, 1H), 1.81 – 1.68 (m, 
3H), 1.68 – 1.57 (m, 5H), 1.28 – 0.98 (m, 6H), 0.91 – 0.71 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 134.1, 131.9, 123.4, 52.0, 44.5, 37.6, 34.4, 33.5, 33.3, 30.0, 
29.9, 29.8, 26.7, 26.5, 26.4. 
FT-IR (film): 3466, 2356, 1707, 1367, 1051, 871, 722 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C20H27ClNO2: 348.1725, found: 348.1730. 
[]22D = +0.6 (c 1.0, CHCl3); 90% ee, from (S,S)-L1. 
 
 
2-(8-Bromo-1-cyclohexyloctan-3-yl)isoindoline-1,3-dione (13).  The title compound was 
synthesized according to GP-5 from 2-(6-bromo-1-chlorohexyl)isoindoline-1,3-dione and Zn-1.  
The product was purified by column chromatography on silica gel (1:12 Et2O/hexanes).  
Colorless oil. 
(S,S)-L1: 220 mg, 87% yield, 91% ee; (R,R)-L1: 215 mg, 86% yield, 91% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 13.0 
min (minor), 13.9 min (major). 
1H NMR (500 MHz, CDCl3) δ 7.88 – 7.76 (m, 2H), 7.77 – 7.63 (m, 2H), 4.25 – 4.05 (m, 1H), 
3.35 (t, J = 6.8 Hz, 2H), 2.20 – 1.98 (m, 2H), 1.85 – 1.76 (m, 2H), 1.76 – 1.56 (m, 7H), 1.52 – 1.34 
(m, 2H), 1.35 – 1.00 (m, 8H), 0.90 – 0.73 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 134.0, 132.0, 123.3, 52.6, 37.6, 34.5, 33.9, 33.6, 33.3, 32.7, 
32.5, 30.0, 28.0, 26.7, 26.5, 26.4, 26.0. 
FT-IR (film): 3465, 2354, 1704, 1379, 1047, 868, 722 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C22H31BrNO2: 420.2, found: 420.1. 




2-(8-(3-Chloro-1H-indazol-1-yl)-1-cyclohexyloctan-3-yl)isoindoline-1,3-dione (14).  The 
title compound was synthesized according to GP-5 from 2-(1-chloro-6-(3-chloro-1H-indazol-1-
yl)hexyl)isoindoline-1,3-dione and Zn-1.  The product was purified by column 
chromatography on silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 249 mg, 84% yield, 88% ee; (R,R)-L1: 249 mg, 84% yield, 87% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK ID-3 column (20% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 5.9 
min (minor), 6.2 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.77 (m, 2H), 7.74 – 7.67 (m, 2H), 7.64 (dt, J = 8.2, 1.0 Hz, 
1H), 7.41 – 7.35 (m, 1H), 7.32 (dt, J = 8.6, 1.0 Hz, 1H), 7.20 – 7.12 (m, 1H), 4.25 (t, J = 7.1 Hz, 2H), 
4.16 – 4.05 (m, 1H), 2.12 – 1.96 (m, 2H), 1.92 – 1.78 (m, 2H), 1.71 – 1.54 (m, 7H), 1.41 – 0.96 (m, 
10H), 0.89 – 0.71 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 168.9, 140.9, 134.0, 132.6, 131.9, 127.4, 123.3, 121.14, 121.06, 
119.9, 109.4, 52.6, 49.2, 37.6, 34.4, 33.5, 33.3, 32.4, 30.0, 29.8, 26.7, 26.6, 26.5, 26.41, 26.38. 
FT-IR (film): 3468, 2353, 1709, 1365, 1049, 873, 728, 682 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C29H35ClN3O2: 492.2412, found: 492.2420. 
[]22D = +3.3 (c 1.0, CHCl3); 88% ee, from (S,S)-L1. 
 
 
8-Cyclohexyl-6-(1,3-dioxoisoindolin-2-yl)octyl (2S)-2-(4-isobutylphenyl)propanoate (15, 
16).  The title compound was synthesized according to GP-5 from 6-chloro-6-(1,3-
dioxoisoindolin-2-yl)hexyl (2S)-2-(4-isobutylphenyl)propanoate and Zn-1.  The product was 
purified by column chromatography on silica gel (1:9 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 279 mg, 85% yield, 95:5 d.r.; (R,R)-L1: 287 mg, 88% yield, 5:95 d.r. 
SFC analysis: The d.r. was determined via SFC on a CHIRALPAK IG-3 column (10% MeOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 9.8 
min (minor), 12.4 min (major). 
NMR data for the product from (S,S)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H), 7.74 – 7.67 (m, 2H), 7.20 – 7.14 (m, 2H), 
7.10 – 7.04 (m, 2H), 4.17 – 4.06 (m, 1H), 3.99 (t, J = 6.6 Hz, 2H), 3.64 (q, J = 7.1 Hz, 1H), 2.43 (d, J 
= 7.2 Hz, 2H), 2.12 – 1.96 (m, 2H), 1.89 – 1.76 (m, 1H), 1.75 – 1.59 (m, 7H), 1.55 – 1.48 (m, 2H), 
1.45 (d, J = 7.2 Hz, 3H), 1.33 – 0.98 (m, 10H), 0.88 (d, J = 6.6 Hz, 6H), 0.86 – 0.73 (m, 2H). 
S–31 
13C NMR (101 MHz, CDCl3) δ 174.9, 168.9, 140.6, 138.0, 134.0, 132.0, 129.4, 127.3, 123.3, 64.7, 
52.7, 45.3, 45.2, 37.6, 34.5, 33.6, 33.3, 32.5, 30.3, 30.0, 28.5, 26.7, 26.5, 26.4, 25.7, 22.5, 18.6. 
NMR data for the product from (R,R)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 2H), 7.74 – 7.67 (m, 2H), 7.21 – 7.14 (m, 2H), 
7.11 – 7.04 (m, 2H), 4.17 – 4.07 (m, 1H), 3.99 (t, J = 6.6 Hz, 2H), 3.65 (q, J = 7.2 Hz, 1H), 2.43 (d, J 
= 7.2 Hz, 2H), 2.12 – 1.97 (m, 2H), 1.89 – 1.77 (m, 1H), 1.72 – 1.58 (m, 7H), 1.56 – 1.48 (m, 2H), 
1.45 (d, J = 7.2 Hz, 3H), 1.33 – 0.98 (m, 10H), 0.88 (d, J = 6.6 Hz, 6H), 0.86 – 0.73 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 174.9, 168.9, 140.6, 138.0, 134.0, 132.0, 129.4, 127.3, 123.3, 64.7, 
52.7, 45.3, 45.2, 37.6, 34.5, 33.6, 33.3, 32.5, 30.3, 30.0, 28.5, 26.7, 26.5, 26.4, 25.7, 22.5, 18.6. 
FT-IR (film): 3468, 2919, 2354, 1710, 1030, 682 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C35H48NO4: 546.3578, found: 546.3576. 
[]22D = +16.9 (c 1.0, CHCl3); 95:5 d.r., from (S,S)-L1. 
[]22D = +14.9 (c 1.0, CHCl3); 5:95 d.r., from (R,R)-L1. 
 
 
2-(Nonan-3-yl)isoindoline-1,3-dione (17).  The title compound was synthesized according 
to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-2.  The product was purified by 
column chromatography on silica gel (1:10 Et2O/hexanes).  Colorless oil. 
(S,S)-L1: 153 mg, 93% yield, 89% ee; (R,R)-L1: 153 mg, 93% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IF-3 column (2% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 5.3 
min (minor), 5.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H), 7.73 – 7.67 (m, 2H), 4.16 – 4.05 (m, 1H), 
2.13 – 1.98 (m, 2H), 1.83 – 1.65 (m, 2H), 1.35 – 1.14 (m, 8H), 0.90 – 0.78 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 123.2, 54.1, 32.4, 31.8, 29.1, 26.8, 25.7, 22.7, 
14.2, 11.3. 
FT-IR (film): 3464, 2921, 2364, 1714, 1360, 1041, 796, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C17H24NO2: 274.1802, found: 274.1807. 
[]22D = −6.1 (c 1.0, CHCl3); 89% ee, from (S,S)-L1. 
 
 
2-(1-Cyclohexylbutan-2-yl)isoindoline-1,3-dione (18).  The title compound was 
synthesized according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-3.  The 
product was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  
Colorless oil. 
(S,S)-L1: 163 mg, 95% yield, 95% ee; (R,R)-L1: 167 mg, 98% yield, 95% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 4.4 
min (minor), 4.9 min (major). 
S–32 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H), 7.73 – 7.66 (m, 2H), 4.29 – 4.19 (m, 1H), 
2.13 – 1.96 (m, 2H), 1.91 – 1.80 (m, 1H), 1.78 – 1.44 (m, 6H), 1.20 – 1.05 (m, 4H), 0.99 – 0.78 (m, 
5H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 123.2, 51.3, 39.9, 34.8, 33.9, 32.7, 26.6, 26.4, 
26.2, 26.1, 11.3. 
FT-IR (film): 3463, 2924, 2356, 1708, 1371, 1064, 886, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H24NO2: 286.1802, found: 286.1806. 
[]22D = −18.0 (c 1.0, CHCl3); 95% ee, from (S,S)-L1. 
 
 
2-(5-Methylhexan-3-yl)isoindoline-1,3-dione (19).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-4.  The product was 
purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 133 mg, 90% yield, 94% ee; (R,R)-L1: 135 mg, 92% yield, 93% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (2% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 4.3 
min (minor), 4.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.78 (m, 2H), 7.73 – 7.66 (m, 2H), 4.27 – 4.17 (m, 1H), 
2.20 – 1.97 (m, 2H), 1.80 – 1.66 (m, 1H), 1.50 – 1.38 (m, 2H), 0.95 – 0.82 (m, 9H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 123.2, 52.0, 41.3, 26.1, 25.4, 23.4, 21.9, 11.3. 
FT-IR (film): 3460, 2956, 2354, 1770, 1470, 1336, 1174, 1062, 867, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C15H20NO2: 246.1489, found: 246.1490. 
[]22D = +1.3 (c 1.0, CHCl3); 94% ee, from (S,S)-L1. 
 
 
2,2'-(Nonane-1,7-diyl)bis(isoindoline-1,3-dione) (20).  The title compound was 
synthesized according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-5.  The 
product was purified by column chromatography on silica gel (1:2 EtOAc/hexanes).  
Colorless oil. 
(S,S)-L1: 238 mg, 95% yield, 91% ee; (R,R)-L1: 230 mg, 92% yield, 92% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK ID-3 column (35% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 9.5 
min (minor), 12.3 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.78 (m, 4H), 7.74 – 7.65 (m, 4H), 4.14 – 4.03 (m, 1H), 
3.63 (t, J = 7.3 Hz, 2H), 2.14 – 1.96 (m, 2H), 1.83 – 1.66 (m, 2H), 1.64 – 1.56 (m, 2H), 1.41 – 1.16 
(m, 6H), 0.84 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 168.6, 133.9, 133.9, 132.3, 132.0, 123.3, 123.2, 54.0, 38.1, 
32.3, 29.0, 28.7, 26.9, 26.7, 25.7, 11.3. 
FT-IR (film): 3465, 2934, 2354, 1708, 1369, 1047, 889, 721 cm-1. 
S–33 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H27N2O4: 419.1965, found: 419.1975. 
[]22D = −5.8 (c 1.0, CHCl3); 91% ee, from (S,S)-L1. 
 
 
2-(8-(Benzyloxy)octan-3-yl)isoindoline-1,3-dione (21).  The title compound was 
synthesized according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-6.  The 
product was purified by column chromatography on silica gel (1:12 EtOAc/hexanes).  
Colorless oil. 
(S,S)-L1: 219 mg, 99% yield, 89% ee; (R,R)-L1: 222 mg, 99% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IE-3 column (10% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 6.6 
min (minor), 7.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 2H), 7.74 – 7.67 (m, 2H), 7.35 – 7.28 (m, 4H), 
7.28 – 7.23 (m, 1H), 4.46 (s, 2H), 4.17 – 4.04 (m, 1H), 3.41 (t, J = 6.5 Hz, 2H), 2.15 – 1.98 (m, 2H), 
1.83 – 1.66 (m, 2H), 1.61 – 1.51 (m, 2H), 1.46 – 1.17 (m, 4H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 138.8, 134.0, 132.0, 128.5, 127.7, 127.6, 123.2, 73.0, 70.4, 
54.0, 32.3, 29.7, 26.7, 26.0, 25.7, 11.3. 
FT-IR (film): 3462, 2922, 2354, 1708, 1367, 1066, 890, 721 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H28NO3: 366.2064, found: 366.2064. 
[]22D = −5.2 (c 1.0, CHCl3); 89% ee, from (S,S)-L1. 
 
 
2-(7-((tert-Butyldimethylsilyl)oxy)heptan-3-yl)isoindoline-1,3-dione (22).  The title 
compound was synthesized according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione 
and Zn-7.  The product was purified by column chromatography on silica gel (1:9 
EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 222 mg, 99% yield, 89% ee; (R,R)-L1: 225 mg, 99% yield, 89% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (2% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 5.1 
min (minor), 5.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.78 (m, 2H), 7.73 – 7.67 (m, 2H), 4.20 – 4.03 (m, 1H), 
3.54 (t, J = 6.4 Hz, 2H), 2.15 – 1.98 (m, 2H), 1.83 – 1.67 (m, 2H), 1.58 – 1.40 (m, 2H), 1.35 – 1.22 
(m, 2H), 0.86 (t, J = 7.4 Hz, 3H), 0.81 (s, 9H), –0.02 (d, J = 2.0 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 123.2, 63.0, 54.0, 32.5, 32.1, 26.0, 25.7, 23.1, 
18.4, 11.3, –5.20, –5.22. 
FT-IR (film): 3468, 2354, 1714, 1470, 1250, 1101, 840, 721 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H34NO3Si: 376.2302, found: 376.2305. 




5-(1,3-Dioxoisoindolin-2-yl)heptyl acetate (23).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-8.  The product was 
purified by column chromatography on silica gel (1:2 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 140 mg, 77% yield, 90% ee; (R,R)-L1: 145 mg, 80% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IF-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 3.7 
min (minor), 4.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.79 (m, 2H), 7.73 – 7.68 (m, 2H), 4.17 – 4.07 (m, 1H), 
4.05 – 3.93 (m, 2H), 2.18 – 2.00 (m, 2H), 1.98 (s, 3H), 1.82 – 1.54 (m, 4H), 1.40 – 1.22 (m, 2H), 0.86 
(t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.3, 169.0, 134.0, 131.9, 123.3, 64.3, 53.8, 31.9, 28.3, 25.7, 23.2, 
21.1, 11.3. 
FT-IR (film): 3460, 2354, 1714, 1367, 1232, 1050, 860, 721 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C17H22NO4: 304.1543, found: 304.1549. 
[]22D = −9.7 (c 1.0, CHCl3); 90% ee, from (S,S)-L1. 
 
 
Ethyl 7-(1,3-dioxoisoindolin-2-yl)nonanoate (24).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-9.  The product was 
purified by column chromatography on silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 186 mg, 94% yield, 89% ee; (R,R)-L1: 193 mg, 97% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IF-3 column (5% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 5.9 
min (minor), 6.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H), 7.75 – 7.65 (m, 2H), 4.19 – 4.07 (m, 1H), 
4.08 (q, J = 7.2 Hz, 2H), 2.23 (t, J = 7.2 Hz, 2H), 2.15 – 1.96 (m, 2H), 1.83 – 1.66 (m, 2H), 1.65 – 1.48 
(m, 2H), 1.44 – 1.15 (m, 4H), 1.22 (t, J = 7.2 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.8, 169.0, 134.0, 131.9, 123.2, 60.3, 53.9, 34.4, 32.2, 28.9, 26.5, 
25.7, 24.9, 14.4, 11.2. 
FT-IR (film): 3462, 2925, 2354, 1714, 1367, 1192, 1058, 861, 721 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H26NO4: 332.1856, found: 332.1867. 
[]22D = −7.3 (c 1.0, CHCl3); 89% ee, from (S,S)-L1. 
 
 
2-(8-Fluorooctan-3-yl)isoindoline-1,3-dione (25).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-10.  The product was 
purified by column chromatography on silica gel (1:12 EtOAc/hexanes).  Colorless oil. 
S–35 
(S,S)-L1: 158 mg, 95% yield, 90% ee; (R,R)-L1: 154 mg, 93% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IF-3 column (3% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 3.7 
min (minor), 4.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.78 (m, 2H), 7.75 – 7.67 (m, 2H), 4.44 (t, J = 6.1 Hz, 1H), 
4.32 (t, J = 6.1 Hz, 1H), 4.17 – 4.06 (m, 1H), 2.17 – 1.99 (m, 2H), 1.82 – 1.55 (m, 4H), 1.50 – 1.18 
(m, 4H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 134.0, 131.9, 123.3, 84.1 (d, J = 165 Hz), 53.9, 32.2, 30.3 
(d, J = 19.2 Hz), 26.4, 25.7, 25.0 (d, J = 5.1 Hz), 11.3. 
19F NMR (376 MHz, CDCl3) δ –218.2. 
FT-IR (film): 3463, 2352, 1708, 1367, 1049, 892, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C16H21FNO2: 278.1551, found: 278.1554. 
[]22D = −4.2 (c 1.0, CHCl3); 90% ee, from (S,S)-L1. 
 
 
2-(7-Chloroheptan-3-yl)isoindoline-1,3-dione (26).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-11.  The product was 
purified by column chromatography on silica gel (1:9 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 144 mg, 86% yield, 91% ee; (R,R)-L1: 153 mg, 91% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK AD-3 column (2% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 9.2 
min (minor), 10.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.79 (m, 2H), 7.75 – 7.67 (m, 2H), 4.18 – 4.06 (m, 1H), 
3.47 (t, J = 6.6 Hz, 2H), 2.19 – 1.98 (m, 2H), 1.85 – 1.67 (m, 4H), 1.49 – 1.31 (m, 2H), 0.86 (t, J = 7.4 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 134.0, 131.9, 123.3, 53.7, 44.9, 32.3, 31.6, 25.7, 24.1, 11.3. 
FT-IR (film): 3461, 2928, 2353, 1710, 1369, 1168, 1054, 790, 720 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C15H19ClNO2: 280.1099, found: 280.1099. 
[]22D = −9.4 (c 1.0, CHCl3); 91% ee, from (S,S)-L1. 
 
 
7-(1,3-Dioxoisoindolin-2-yl)nonanenitrile (27).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-12.  The product was 
purified by column chromatography on silica gel (1:3 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 157 mg, 92% yield, 90% ee; (R,R)-L1: 160 mg, 94% yield, 89% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IF-3 column (10% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 3.6 
min (minor), 3.8 min (major). 
S–36 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 2H), 7.75 – 7.68 (m, 2H), 4.16 – 4.05 (m, 1H), 
2.29 (t, J = 7.1 Hz, 2H), 2.18 – 1.99 (m, 2H), 1.84 – 1.65 (m, 2H), 1.65 – 1.56 (m, 2H), 1.56 – 1.17 
(m, 4H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 134.1, 131.9, 123.3, 119.8, 53.8, 32.0, 28.4, 26.0, 25.7, 25.4, 
17.2, 11.2. 
FT-IR (film): 3460, 2918, 2246, 1705, 1366, 1056, 864, 728 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C17H21N2O2: 285.1598, found: 285.1605. 
[]22D = −4.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L1. 
 
 
2-(8-Phenyloct-7-yn-3-yl)isoindoline-1,3-dione (28).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-13.  The product was 
purified by column chromatography on silica gel (1:9 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 151 mg, 76% yield, 91% ee; (R,R)-L1: 159 mg, 80% yield, 91% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALCEL OD-3 column (10% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 6.7 
min (major), 7.4 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.89 – 7.80 (m, 2H), 7.76 – 7.68 (m, 2H), 7.43 – 7.34 (m, 2H), 
7.32 – 7.23 (m, 3H), 4.25 – 4.13 (m, 1H), 2.43 (t, J = 7.1 Hz, 2H), 2.34 – 2.21 (m, 1H), 2.19 – 2.03 
(m, 1H), 2.00 – 1.89 (m, 1H), 1.89 – 1.76 (m, 1H), 1.63 – 1.51 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.9, 134.0, 131.9, 131.7, 128.3, 127.7, 124.0, 123.3, 89.7, 81.2, 
53.5, 31.5, 26.0, 25.8, 19.2, 11.3. 
FT-IR (film): 3461, 2928, 2234, 1709, 1366, 1048, 797, 726 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C22H22NO2: 332.1645, found: 332.1644. 
[]22D = −10.7(c 1.0, CHCl3); 91% ee, from (S,S)-L1. 
 
 
2-(Non-8-en-3-yl)isoindoline-1,3-dione (29).  The title compound was synthesized 
according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-14.  The product was 
purified by column chromatography on silica gel (1:5 Et2O/hexanes).  Colorless oil. 
(S,S)-L1: 101 mg, 62% yield, 89% ee; (R,R)-L1: 98 mg, 60% yield, 89% ee. 
SFC Analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (2% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 7.3 
min (minor), 8.2 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.79 (m, 2H), 7.74 – 7.68 (m, 2H), 5.84 – 5.66 (m, 1H), 
5.05 – 4.77 (m, 2H), 4.18 – 4.04 (m, 1H), 2.15 – 1.94 (m, 4H), 1.84 – 1.66 (m, 2H), 1.49 – 1.16 (m, 
4H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 138.9, 134.0, 132.0, 123.2, 114.5, 54.0, 33.7, 32.2, 28.7, 
26.3, 25.7, 11.3. 
S–37 
FT-IR (film): 3466, 2926, 2359, 1710, 1358, 1048, 911, 723 cm-1.  
HRMS (ESI-MS) m/z [M+H]+ calcd for C17H22NO2: 272.1645, found: 272.1632. 
[]22D = −8.7 (c 1.0, CHCl3); 89% ee, from (S,S)-L1. 
 
 
2-((6S)-6,10-Dimethylundec-9-en-3-yl)isoindoline-1,3-dione (30, 31).  The title compound 
was synthesized according to GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-15.  
The product was purified by column chromatography on silica gel (1:12 EtOAc/hexanes).  
Colorless oil. 
(S,S)-L1: 150 mg, 77% yield, 96:4 d.r.; (R,R)-L1: 153 mg, 78% yield, 4:96 d.r. 
SFC analysis: The d.r. was determined via SFC on a CHIRALPAK IF-3 column (2% CH3CN 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 9.1 
min (minor), 11.9 min (major). 
NMR data for the product from (S,S)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.79 (m, 2H), 7.74 – 7.67 (m, 2H), 5.08 – 4.99 (m, 1H), 
4.12 – 4.01 (m, 1H), 2.14 – 1.71 (m, 6H), 1.64 (s, 3H), 1.54 (s, 3H), 1.46 – 1.01 (m, 5H), 0.86 (t, J = 
7.6 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 131.2, 125.0, 123.2, 54.6, 36.9, 34.1, 32.4, 
29.9, 25.8, 25.7, 25.6, 19.7, 17.7, 11.3. 
NMR data for the product from (R,R)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.79 (m, 2H), 7.74 – 7.67 (m, 2H), 5.08 – 5.00 (m, 1H), 
4.14 – 4.02 (m, 1H), 2.17 – 1.99 (m, 2H), 1.98 – 1.67 (m, 4H), 1.65 (s, 3H), 1.54 (s, 3H), 1.46 – 1.17 
(m, 3H), 1.16 – 0.95 (m, 2H), 0.86 (t, J = 7.6 Hz, 3H), 0.82 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 133.9, 132.0, 131.2, 125.0, 123.2, 54.4, 37.1, 33.9, 32.2, 
29.7, 25.83, 25.81, 25.6, 19.6, 17.7, 11.3. 
FT-IR (film): 3465, 2922, 1709, 1455, 1368, 1062, 884, 718 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H30NO2: 328.2271, found: 328.2273. 
[]22D = +0.8 (c 1.0, CHCl3); 96:4 d.r., from (S,S)-L1. 





dioxoisoindolin-2-yl)heptanoate (32, 33).  The title compound was synthesized according to 
S–38 
GP-5 from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-16.  The product was purified by 
column chromatography on silica gel (1:15 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 336 mg, 87% yield, 92:8 d.r.; (R,R)-L1: 324 mg, 84% yield, 8:92 d.r. 
SFC analysis: The d.r. was determined via SFC on a CHIRALPAK IG-3 column (25% MeOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 10.7 
min (minor), 11.7 min (major). 
NMR data for the product from (S,S)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.77 (m, 2H), 7.75 – 7.66 (m, 2H), 5.39 – 5.31 (m, 1H), 
4.63 – 4.51 (m, 1H), 4.19 – 4.06 (m, 1H), 2.35 – 2.20 (m, 4H), 2.19 – 1.90 (m, 4H), 1.88 – 1.69 (m, 
5H), 1.64 – 1.40 (m, 9H), 1.40 – 1.21 (m, 4H), 1.21 – 1.04 (m, 7H), 1.03 – 0.89 (m, 9H), 0.88 – 0.81 
(m, 9H), 0.67 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.8, 168.9, 139.8, 134.0, 131.9, 123.3, 122.7, 74.0, 56.8, 56.3, 
53.6, 50.1, 42.4, 39.9, 39.6, 38.2, 37.1, 36.7, 36.3, 35.9, 34.3, 32.02, 31.98, 31.7, 28.4, 28.1, 27.9, 25.7, 
24.4, 24.0, 23.0, 22.7, 22.3, 21.2, 19.4, 18.8, 12.0, 11.2. 
NMR data for the product from (R,R)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.85 – 7.77 (m, 2H), 7.74 – 7.67 (m, 2H), 5.38 – 5.29 (m, 1H), 
4.62 – 4.50 (m, 1H), 4.18 – 4.07 (m, 1H), 2.35 – 2.20 (m, 4H), 2.20 – 1.90 (m, 4H), 1.90 – 1.67 (m, 
5H), 1.65 – 1.40 (m, 9H), 1.40 – 1.22 (m, 4H), 1.22 – 1.02 (m, 7H), 1.03 – 0.88 (m, 9H), 0.88 – 0.81 
(m, 9H), 0.66 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.8, 168.9, 139.8, 134.0, 131.9, 123.3, 122.7, 74.0, 56.8, 56.3, 
53.6, 50.1, 42.4, 39.9, 39.6, 38.2, 37.1, 36.7, 36.3, 35.9, 34.2, 32.02, 31.97, 31.7, 28.4, 28.1, 27.9, 25.7, 
24.4, 24.0, 23.0, 22.7, 22.3, 21.2, 19.4, 18.8, 12.0, 11.2. 
FT-IR (film): 3460, 2353, 1714, 1361, 1168, 1020, 892, 721 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C42H65N2O4: 661.4939, found: 661.4949. 
[]22D = −26.4 (c 1.0, CHCl3); 92:8 d.r., from (S,S)-L1. 





yl)isoindoline-1,3-dione (34, 35).  The title compound was synthesized according to GP-5 
from 2-(1-chloropropyl)isoindoline-1,3-dione and Zn-17.  The product was purified by 
column chromatography on silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
(S,S)-L1: 307 mg, 90% yield, 94:6 d.r.; (R,R)-L1: 300 mg, 88% yield, 6:94 d.r. 
SFC analysis: The d.r. was determined via SFC on a CHIRALCEL OJ-3 column (20% i-
PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L1: 
7.0 min (major), 7.5 min (minor). 
S–39 
NMR data for the product from (S,S)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 2H), 7.74 – 7.65 (m, 2H), 7.16 (d, J = 8.7 Hz, 1H), 
6.65 (dd, J = 8.6, 2.8 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 4.17 – 4.07 (m, 1H), 3.99 – 3.83 (m, 6H), 2.90 
– 2.74 (m, 2H), 2.37 – 2.17 (m, 2H), 2.17 – 1.97 (m, 3H), 1.92 – 1.58 (m, 9H), 1.56 – 1.23 (m, 9H), 
0.874 (s, 3H), 0.865 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 157.0, 138.1, 134.0, 132.7, 132.0, 126.4, 123.2, 119.6, 114.6, 
112.2, 67.8, 65.4, 64.7, 54.0, 49.5, 46.3, 43.8, 39.2, 34.4, 32.3, 30.9, 29.9, 29.3, 27.2, 26.6, 26.3, 25.9, 
25.7, 22.5, 14.5, 11.3. 
NMR data for the product from (R,R)-L1: 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 2H), 7.75 – 7.66 (m, 2H), 7.16 (d, J = 8.7 Hz, 1H), 
6.65 (dd, J = 8.6, 2.7 Hz, 1H), 6.58 (d, J = 2.7 Hz, 1H), 4.19 – 4.06 (m, 1H), 4.02 – 3.80 (m, 6H), 2.91 
– 2.73 (m, 2H), 2.37 – 2.17 (m, 2H), 2.17 – 1.96 (m, 3H), 1.95 – 1.57 (m, 9H), 1.57 – 1.24 (m, 9H), 
0.88 (s, 3H), 0.87 (t, J = 7.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 157.0, 138.0, 134.0, 132.6, 132.0, 126.4, 123.2, 119.6, 114.6, 
112.1, 67.8, 65.4, 64.7, 54.0, 49.5, 46.3, 43.8, 39.2, 34.4, 32.3, 30.9, 29.9, 29.3, 27.1, 26.6, 26.3, 25.9, 
25.7, 22.5, 14.5, 11.3. 
FT-IR (film): 3460, 2918, 2352, 1709, 1605, 1470, 1366, 1246, 1050, 724 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C36H46NO5: 572.3371, found: 572.3368. 
[]22D = +9.5 (c 1.0, CHCl3); 94:6 d.r., from (S,S)-L1. 
[]22D = +20.4 (c 1.0, CHCl3); 6:94 d.r., from (R,R)-L1. 
 
 
tert-Butyl (5-phenoxypentan-2-yl)carbamate (36).  The title compound was synthesized 
according to GP-6 from 1,3-dioxoisoindolin-2-yl (tert-butoxycarbonyl)alaninate and Zn-18.  
The product was purified by column chromatography on silica gel (1:4 EtOAc/hexanes).  
White solid. 
(S,S)-L2: 109 mg, 65% yield, 90% ee; (R,R)-L2: 114 mg, 68% yield, 90% ee. 
After recrystallization using n-pentane/hexanes: (S,S)-L2: 92 mg, 90% ee → 66 mg, 72% 
yield (47% yield overall), >99% ee; (R,R)-L2: 86 mg, 90% ee → 65 mg, 76% yield (51% yield 
overall), >99% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 12.3 min 
(minor), 17.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.22 (m, 2H), 6.97 – 6.87 (m, 3H), 4.41 (d, J = 8.6 Hz, 1H), 
3.96 (td, J = 6.3, 1.2 Hz, 2H), 3.70 (q, J = 7.7, 7.2 Hz, 1H), 1.89 – 1.77 (m, 2H), 1.68 – 1.51 (m, 2H), 
1.45 (s, 9H), 1.16 (d, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 155.5, 129.5, 120.7, 114.6, 79.1, 67.6, 46.4, 34.0, 28.6, 26.1, 
21.6. 
FT-IR (film): 3372, 2967, 1690, 1499, 1247, 1173, 751 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C16H26NO3: 280.1907, found: 280.1912. 
S–40 
[]23D = –6.2 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (6-phenoxyhexan-3-yl)carbamate (37).  The title compound was synthesized 
according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)butanoate and 
Zn-18.  The product was purified by column chromatography on silica gel (1:4 
EtOAc/hexanes).  White solid. 
(S,S)-L2: 137 mg, 79% yield, 90% ee; (R,R)-L2: 143 mg, 81% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 8.4 min 
(major), 9.1 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.23 (m, 2H), 6.97 – 6.85 (m, 3H), 4.36 – 4.30 (m, 1H), 
3.97 (t, J = 6.3 Hz, 2H), 3.62 – 3.48 (m, 1H), 1.93 – 1.77 (m, 2H), 1.73 – 1.52 (m, 2H), 1.47 – 1.42 
(m, 11H), 0.92 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 156.0, 129.5, 120.7, 114.6, 79.1, 67.7, 51.9, 31.8, 28.6, 26.0, 
10.4. 
FT-IR (film): 3345, 2966, 1698, 1498, 1246, 1174, 1091, 754, 692 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C17H28NO3: 294.2064, found: 294.2061. 
[]23D = –9.9 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (6-methyl-1-phenoxyheptan-4-yl)carbamate (38).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl (tert-butoxycarbonyl)leucinate 
and Zn-18.  The product was purified by column chromatography on silica gel (15:85 
EtOAc/hexanes).  White solid. 
(S,S)-L2: 139 mg, 72% yield, 90% ee; (R,R)-L2: 134 mg, 70% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK AD column (5% i-PrOH in 
supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L2: 5.2 min 
(minor), 6.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.21 (m, 2H), 6.97 – 6.86 (m, 3H), 4.26 (d, J = 9.4 Hz, 1H), 
3.97 (t, J = 6.3 Hz, 2H), 3.76 – 3.63 (m, 1H), 1.92 – 1.74 (m, 2H), 1.74 – 1.60 (m, 2H), 1.45 – 1.42 
(m, 10H), 1.35 – 1.22 (m, 2H), 0.91 (dd, J = 6.6, 4.1 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 155.8, 129.5, 120.7, 114.6, 79.0, 67.8, 48.7, 45.3, 32.8, 28.6, 
25.9, 25.1, 23.3, 22.4. 
FT-IR (film): 3346, 2918, 1691, 1497, 1246, 1173, 1037, 755, 692 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H32NO3: 322.2377, found: 322.2378. 




tert-Butyl (1-cyclohexyl-4-phenoxybutyl)carbamate (39).  The title compound was 
synthesized according to GP-7 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-2-
cyclohexylacetate and Zn-18.  The product was purified by column chromatography on silica 
gel (1:4 EtOAc/hexanes).  White solid. 
(S,S)-L2: 138 mg, 66% yield, 88% ee; (R,R)-L2: 142 mg, 68% yield, 88% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 8.0 min 
(major), 14.2 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.70 – 6.73 (m, 5H), 4.52 – 4.28 (m, 1H), 3.97 (t, J = 6.1 Hz, 2H), 
3.57 – 3.33 (m, 1H), 1.99 – 1.58 (m, 9H), 1.49 – 1.38 (m, 10H), 1.38 – 0.84 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 156.1, 155.8, 150.6, 129.6, 129.5, 126.2, 121.6, 120.7, 114.6, 
80.1, 79.0, 67.7, 66.0, 58.6, 55.0, 42.6, 41.3, 29.8, 29.7, 29.2, 28.6, 28.5, 28.4, 26.6, 26.44, 26.42, 26.3, 
26.2, 26.1. 
FT-IR (film): 3348, 2927, 2853, 1704, 1496, 1246, 1166, 753, 691 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H34NO3: 348.2533, found: 348.2539. 
[]23D = –5.3 (c 1.0, CHCl3); 88% ee, from (S,S)-L2. 
 
 
tert-Butyl (2-methyl-6-phenoxyhexan-3-yl)carbamate (40).  The title compound was 
synthesized according to GP-7 from 1,3-dioxoisoindolin-2-yl (tert-butoxycarbonyl)valinate and 
Zn-18.  The product was purified by column chromatography on silica gel (1:4 
EtOAc/hexanes).  White solid. 
(S,S)-L2: 122 mg, 66% yield, 89% ee; (R,R)-L2: 115 mg, 62% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 7.7 min 
(minor), 13.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.48 – 6.83 (m, 5H), 4.55 – 4.25 (m, 1H), 3.97 (t, J = 6.2 Hz, 2H), 
3.55 – 3.39 (m, 1H), 1.98 – 1.34 (m, 14H), 1.19 – 0.82 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 156.2, 155.8, 150.5, 129.6, 129.5, 126.2, 121.5, 120.7, 114.6, 
80.1, 79.0, 67.7, 58.8, 55.4, 32.5, 31.5, 29.3, 28.6, 28.4, 26.3, 19.2, 17.8. 
FT-IR (film): 3356, 2963, 1703, 1498, 1246, 1174, 754, 691 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H30NO3: 308.2222, found: 308.2216. 
[]23D = +0.4 (c 1.0, CHCl3); 89% ee, from (S,S)-L2. 
 
 
tert-Butyl (6-phenoxy-1-phenylhexan-3-yl)carbamate (41).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
S–42 
phenylbutanoate and Zn-18.  The product was purified by column chromatography on silica 
gel (1:4 EtOAc/hexanes).  White solid. 
(S,S)-L2: 176 mg, 79% yield, 90% ee; (R,R)-L2: 181 mg, 82% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (3% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 9.1 min 
(minor), 12.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 4H), 7.22 – 7.15 (m, 3H), 6.98 – 6.88 (m, 3H), 
4.38 (d, J = 9.4 Hz, 1H), 3.97 (t, J = 6.2 Hz, 2H), 3.75 – 3.65 (m, 1H), 2.77 – 2.59 (m, 2H), 1.93 – 
1.50 (m, 6H), 1.46 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 155.9, 142.1, 129.6, 128.54, 128.50, 126.0, 120.7, 114.6, 
79.2, 67.6, 50.5, 37.9, 32.5, 32.4, 28.6, 25.9. 
FT-IR (film): 3344, 2932, 1704, 1496, 1246, 1168, 1037, 753, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H32NO3: 370.2377, found: 370.2377. 
[]23D = +3.9 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (5-phenoxy-1-phenylpentan-2-yl)carbamate (42).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl (tert-
butoxycarbonyl)phenylalaninate and Zn-18.  The product was purified by column 
chromatography on silica gel (1:3 EtOAc/hexanes).  White solid. 
(S,S)-L2: 162 mg, 76% yield, 90% ee; (R,R)-L2: 164 mg, 77% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 13.1 min 
(minor), 14.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.17 (m, 7H), 6.98 – 6.90 (m, 1H), 6.89 – 6.84 (m, 2H), 
4.41 (d, J = 9.1 Hz, 1H), 3.94 (t, J = 6.2 Hz, 2H), 3.88 (s, 1H), 2.88 – 2.73 (m, 2H), 1.95 – 1.64 (m, 
4H), 1.41 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.0, 155.6, 138.2, 129.7, 129.5, 128.5, 126.5, 120.7, 114.6, 79.2, 
67.5, 51.5, 41.7, 30.9, 28.5, 26.1. 
FT-IR (film): 3346, 2932, 1698, 1496, 1365, 1246, 1168, 754, 693 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C22H30NO3: 356.2220, found: 356.2221. 
[]23D = +13.2 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
Di-tert-butyl (8-phenoxyoctane-1,5-diyl)dicarbamate (43).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl N2,N6-bis(tert-
butoxycarbonyl)lysinate and Zn-18.  The product was purified by column chromatography 
on silica gel (1:3 EtOAc/hexanes) and was then extracted in hexanes to separate it from 
phthalimide.  White solid. 
S–43 
(S,S)-L2: 165 mg, 63% yield, 91% ee; (R,R)-L2: 159 mg, 61% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 10.1 min 
(minor), 12.2 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.22 (m, 2H), 6.97 – 6.86 (m, 3H), 4.59 (s, 1H), 4.36 (d, J = 
9.3 Hz, 1H), 3.95 (t, J = 6.2 Hz, 2H), 3.65 – 3.53 (m, 1H), 3.15 – 3.05 (m, 2H), 1.87 – 1.60 (m, 4H), 
1.54 – 1.37 (m, 24H). 
13C NMR (101 MHz, CDCl3) δ 159.0, 156.2, 156.0, 129.5, 120.7, 114.6, 79.1, 67.6, 50.3, 40.5, 
35.7, 32.3, 31.7, 29.9, 28.6, 26.0, 23.2, 22.8, 14.3. 
FT-IR (film): 3348, 2933, 1697, 1521, 1365, 1247, 1169, 752 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C24H40N2NaO5: 459.3, found: 459.3. 
[]23D = –6.9 (c 1.0, CHCl3); 91% ee, from (S,S)-L2. 
 
 
tert-Butyl (1-(methylthio)-6-phenoxyhexan-3-yl)carbamate (44).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl (tert-
butoxycarbonyl)methioninate and Zn-18.  The product was purified by column 
chromatography on silica gel (3:7 EtOAc/hexanes).  White solid. 
(S,S)-L2: 130 mg, 64% yield, 91% ee; (R,R)-L2: 132 mg, 65% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 11.0 min 
(minor), 11.7 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.21 (m, 2H), 6.98 – 6.85 (m, 3H), 4.40 (d, J = 9.3 Hz, 1H), 
3.97 (t, J = 6.1 Hz, 2H), 3.78 – 3.61 (m, 1H), 2.58 – 2.48 (m, 2H), 2.10 (s, 3H), 1.95 – 1.50 (m, 6H), 
1.44 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.0, 155.8, 129.6, 120.8, 114.6, 79.3, 67.5, 50.1, 35.6, 32.2, 30.9, 
28.6, 26.0, 15.8. 
FT-IR (film): 3346, 2918, 1694, 1498, 1246, 1173, 1038, 755, 692 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H30NO3S: 340.1941, found: 340.1949. 
[]23D = –2.1 (c 1.0, CHCl3); 91% ee, from (S,S)-L2. 
 
 
tert-Butyl (1-(1-methyl-1H-indol-3-yl)-5-phenoxypentan-2-yl)carbamate (45).  The title 
compound was synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl Nα-(tert-
butoxycarbonyl)-1-methyltryptophanate and Zn-18.  The product was purified by column 
chromatography on silica gel (35:65 EtOAc/hexanes).  White solid. 
S–44 
(S,S)-L2: 129 mg, 53% yield, 91% ee; (R,R)-L2: 145 mg, 59% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 11.6 min 
(minor), 17.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.66 – 7.59 (m, 1H), 7.31 – 7.17 (m, 4H), 7.15 – 7.07 (m, 1H), 
6.97 – 6.89 (m, 1H), 6.90 – 6.83 (m, 3H), 4.48 (d, J = 9.2 Hz, 1H), 4.02 – 3.92 (m, 3H), 3.75 (s, 3H), 
2.96 (d, J = 5.9 Hz, 2H), 1.96 – 1.69 (m, 4H), 1.44 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 155.8, 137.0, 129.5, 128.6, 127.6, 121.6, 120.7, 119.4, 119.0, 
114.6, 110.6, 109.2, 79.1, 67.6, 50.9, 32.8, 31.1, 30.9, 28.6, 26.2. 
FT-IR (film): 3382, 2934, 1710, 1496, 1247, 1173, 1053, 742 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H33N2O3: 409.2486, found: 409.2481. 
[]23D = +6.9 (c 1.0, CHCl3); 91% ee, from (S,S)-L2. 
 
 
tert-Butyl (5-phenoxy-1-(thiophen-2-yl)pentan-2-yl)carbamate (46).  The title compound 
was synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-
butoxycarbonyl)amino)-3-(thiophen-2-yl)propanoate and Zn-18.  The product was purified 
by column chromatography on silica gel (15:85 EtOAc/hexanes).  White solid. 
(S,S)-L2: 149 mg, 69% yield, 92% ee; (R,R)-L2: 155 mg, 72% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 13.9 min 
(minor), 19.2 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 7.19 – 7.13 (m, 1H), 6.96 – 6.91 (m, 2H), 
6.90 – 6.86 (m, 2H), 6.84 – 6.81 (m, 1H), 4.54 – 4.47 (m, 1H), 3.96 (t, J = 6.2 Hz, 2H), 3.90 – 3.81 
(m, 1H), 3.13 – 2.96 (m, 2H), 1.91 – 1.80 (m, 2H), 1.77 – 1.49 (m, 2H), 1.44 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.0, 155.6, 139.9, 129.6, 127.0, 126.3, 124.2, 120.8, 114.6, 79.4, 
67.4, 51.2, 35.2, 30.7, 28.6, 26.1. 
FT-IR (film): 3338, 2934, 1692, 1498, 1244, 1171, 753, 690 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C20H27NNaO3S: 384.2, found: 384.1. 
[]23D = +17.2 (c 1.0, CHCl3); 92% ee, from (S,S)-L2. 
 
 
Methyl 4-((tert-butoxycarbonyl)amino)-7-phenoxyheptanoate (47).  The title compound 
was synthesized according to GP-6 from 1-(1,3-dioxoisoindolin-2-yl) 5-methyl (tert-
butoxycarbonyl)glutamate and Zn-18.  The product was purified by column chromatography 
S–45 
on silica gel (1:3 EtOAc/hexanes) and was then extracted in hexanes to separate it from 
phthalimide.  White solid. 
(S,S)-L2: 145 mg, 69% yield, 93% ee; (R,R)-L2: 138 mg, 65% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 16.6 min 
(minor), 18.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.23 (m, 2H), 6.95 – 6.86 (m, 3H), 4.34 (d, J = 9.5 Hz, 1H), 
3.96 (t, J = 6.4 Hz, 2H), 3.67 (s, 3H), 3.65 – 3.61 (m, 1H), 2.40 (t, J = 7.5 Hz, 2H), 1.92 – 1.59 (m, 
6H), 1.43 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 174.1, 158.9, 155.7, 129.4, 120.6, 114.5, 79.2, 67.4, 51.7, 50.2, 
32.4, 30.8, 30.7, 28.4, 25.8. 
FT-IR (film): 3367, 2950, 1709, 1498, 1365, 1246, 1173, 756 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C19H29NNaO5: 374.2, found: 374.2. 
[]23D = +0.9 (c 1.0, CHCl3); 93% ee, from (S,S)-L2. 
 
 
tert-Butyl 2-(3-phenoxypropyl)pyrrolidine-1-carboxylate (48).  The title compound was 
synthesized according to GP-6 from 1-(tert-butyl) 2-(1,3-dioxoisoindolin-2-yl) pyrrolidine-1,2-
dicarboxylate and Zn-18.  The product was purified by column chromatography on silica gel 
(1:9 EtOAc/hexanes).  White solid. 
(S,S)-L2: 119 mg, 65% yield, 90% ee; (R,R)-L2: 114 mg, 62% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 8.1 min 
(minor), 9.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.22 (m, 2H), 6.96 – 6.84 (m, 3H), 4.01 – 3.89 (m, 2H), 
3.87 – 3.76 (m, 1H), 3.49 – 3.28 (m, 2H), 1.98 – 1.63 (m, 8H), 1.46 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 154.8, 129.5, 120.6, 114.6, 79.2, 67.7, 57.2, 46.7, 30.9, 28.7, 
26.3, 23.9, 23.2. 
FT-IR (film): 2970, 2873, 1694, 1393, 1246, 1173, 1108, 754, 692 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H28NO3: 306.2064, found: 306.2070. 
[]23D = –39.7 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
(9H-Fluoren-9-yl)methyl (6-phenoxyhexan-3-yl)carbamate (49).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)butanoate and Zn-18.  The product was purified by column 
chromatography on silica gel (2:3 EtOAc/hexanes).  White solid. 
(S,S)-L2: 181 mg, 73% yield, 88% ee; (R,R)-L2: 182 mg, 73% yield, 86% ee. 
S–46 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (15% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 8.7 min 
(major), 9.9 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 7.4 Hz, 2H), 7.40 (t, J = 7.6 
Hz, 2H), 7.36 – 7.23 (m, 4H), 6.98 – 6.87 (m, 3H), 4.53 (d, J = 9.3 Hz, 1H), 4.45 (d, J = 6.7 Hz, 2H), 
4.22 (t, J = 6.7 Hz, 1H), 3.97 (t, J = 6.1 Hz, 2H), 3.69 – 3.57 (m, 1H), 1.88 – 1.36 (m, 6H), 0.92 (t, J = 
7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.1, 156.4, 144.2, 141.5, 129.6, 127.8, 127.2, 125.2, 120.8, 120.1, 
114.6, 67.6, 66.4, 52.6, 47.6, 31.7, 28.5, 25.9, 10.3. 
FT-IR (film): 3323, 2958, 1689, 1541, 1246, 1106, 737, 691 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C27H30NO3: 416.2, found: 416.2. 
[]23D = –8.2 (c 1.0, CHCl3); 87% ee, from (S,S)-L2. 
 
 
Benzyl (6-phenoxyhexan-3-yl)carbamate (50).  The title compound was synthesized 
according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-(((benzyloxy)carbonyl)amino)butanoate and 
Zn-18.  The product was purified by column chromatography on silica gel (3:7 
EtOAc/hexanes).  White solid. 
(S,S)-L2: 149 mg, 76% yield, 88% ee; (R,R)-L2: 155 mg, 79% yield, 88% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 10.8 min 
(minor), 12.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.22 (m, 7H), 6.99 – 6.84 (m, 3H), 5.11 (s, 2H), 4.58 (d, J = 
9.2 Hz, 1H), 3.97 (t, J = 6.2 Hz, 2H), 3.71 – 3.58 (m, 1H), 1.87 – 1.36 (m, 6H), 0.93 (t, J = 7.4 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 159.0, 156.4, 136.8, 129.5, 128.6, 128.19, 128.17, 120.7, 114.6, 
67.6, 66.7, 52.6, 31.6, 28.5, 25.9, 10.3. 
FT-IR (film): 3325, 2961, 1694, 1498, 1244, 1093, 753, 693 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C20H26NO3: 328.2, found: 328.2. 
[]23D = –3.4 (c 1.0, CHCl3); 88% ee, from (S,S)-L2. 
 
 
tert-Butyl (4-phenylbutan-2-yl)carbamate (51).  The title compound was synthesized 
according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-19.  The product was purified by column chromatography on silica 
gel (1:9 EtOAc/hexanes).  White solid. 
(S,S)-L2: 108 mg, 72% yield, 81% ee; (R,R)-L2: 113 mg, 76% yield, 80% ee. 
S–47 
After recrystallization using n-pentane/hexanes: (S,S)-L2: 101 mg, 81% ee → 62 mg, 61% 
yield (44% yield overall), >99% ee; (R,R)-L2: 58 mg, 80% ee → 35 mg, 60% yield (46% yield 
overall), >99% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 8.9 min 
(minor), 11.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.24 (m, 2H), 7.22 – 7.14 (m, 3H), 4.38 (s, 1H), 3.78 – 3.57 
(m, 1H), 2.66 (td, J = 7.6, 3.9 Hz, 2H), 1.79 – 1.66 (m, 2H), 1.46 (s, 9H), 1.16 (d, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.5, 142.1, 128.50, 128.45, 125.9, 79.1, 46.5, 39.3, 32.6, 28.6, 
21.5. 
FT-IR (film): 3372, 2966, 1682, 1520, 1367, 1246, 1075, 744 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C15H24NO2: 250.1802, found: 250.1806. 
[]23D = +10.6 (c 1.0, CHCl3); 81% ee, from (S,S)-L2. 
 
 
tert-Butyl (1-phenylnonan-3-yl)carbamate (52).  The title compound was synthesized 
according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-2.  The product was purified by column chromatography on silica 
gel (1:9 EtOAc/hexanes).  White solid. 
(S,S)-L2: 160 mg, 84% yield, 90% ee; (R,R)-L2: 159 mg, 83% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 5.9 min 
(minor), 7.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 2H), 7.22 – 7.13 (m, 3H), 4.31 (d, J = 9.4 Hz, 1H), 
3.66 – 3.57 (m, 1H), 2.76 – 2.56 (m, 2H), 1.83 – 1.56 (m, 2H), 1.48 – 1.44 (m, 10H), 1.40 – 1.25 (m, 
9H), 0.92 – 0.84 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.3, 128.5, 125.9, 79.0, 50.7, 37.7, 35.8, 32.6, 31.9, 29.4, 
28.6, 25.9, 22.7, 14.2. 
FT-IR (film): 3347, 2930, 1694, 1519, 1366, 1246, 1173, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C20H34NO2: 320.2584, found: 320.2586. 
[]23D = +16.0 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (1-cyclohexyl-4-phenylbutan-2-yl)carbamate (53).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-3.  The product was purified by column chromatography on silica 
gel (1:9 EtOAc/hexanes).  White solid. 
(S,S)-L2: 140 mg, 70% yield, 90% ee; (R,R)-L2: 146 mg, 73% yield, 89% ee. 
S–48 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 5.8 min 
(minor), 7.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.23 (m, 2H), 7.22 – 7.13 (m, 3H), 4.25 (d, J = 9.5 Hz, 1H), 
3.80 – 3.68 (m, 1H), 2.75 – 2.56 (m, 2H), 1.89 – 1.56 (m, 7H), 1.46 (s, 9H), 1.39 – 1.06 (m, 6H), 1.01 
– 0.77 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 155.7, 142.4, 128.5, 128.5, 125.9, 79.0, 48.2, 43.9, 38.4, 34.6, 34.0, 
33.1, 32.5, 28.6, 26.7, 26.5, 26.4. 
FT-IR (film): 3346, 2921, 1698, 1522, 1365, 1247, 1166, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H34NO2: 332.2584, found: 332.2581. 
[]23D = +8.8 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (6-methyl-1-phenylheptan-3-yl)carbamate (54).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-20.  The product was purified by column chromatography on silica 
gel (1:9 EtOAc/hexanes).  White solid. 
(S,S)-L2: 145 mg, 79% yield, 90% ee; (R,R)-L2: 143 mg, 78% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 5.4 min 
(minor), 6.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.19 (d, J = 7.3 Hz, 3H), 4.31 (d, J = 9.4 Hz, 
1H), 3.69 – 3.55 (m, 1H), 2.76 – 2.56 (m, 2H), 1.83 – 1.58 (m, 2H), 1.57 – 1.48 (m, 2H), 1.46 (s, 9H), 
1.42 – 1.30 (m, 1H), 1.29 – 1.13 (m, 2H), 0.91 – 0.83 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.3, 128.5, 125.9, 79.1, 50.9, 37.7, 35.0, 33.6, 32.6, 28.6, 
28.1, 22.8, 22.7. 
FT-IR (film): 3328, 2950, 1681, 1537, 1366, 1176, 1026, 751, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H32NO2: 306.2428, found: 306.2434. 
[]23D = +8.0 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (1,6-diphenylhexan-3-yl)carbamate (55).  The title compound was synthesized 
according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-21.  The product was purified by column chromatography on silica 
gel (1:9 EtOAc/hexanes).  White solid. 
(S,S)-L2: 161 mg, 76% yield, 90% ee; (R,R)-L2: 162 mg, 76% yield, 89% ee. 
S–49 
After recrystallization using n-pentane/hexanes: (S,S)-L2: 150 mg, 90% ee → 125 mg, 83% 
yield (63% yield overall), 97% ee; (R,R)-L2: 105 mg, 89% ee → 83 mg, 79% yield (60% yield 
overall), 97% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 6.3 min 
(minor), 7.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.24 (m, 4H), 7.24 – 7.14 (m, 6H), 4.31 (d, J = 9.4 Hz, 1H), 
3.75 – 3.63 (m, 1H), 2.73 – 2.56 (m, 4H), 1.84 – 1.60 (m, 4H), 1.58 – 1.38 (m, 11H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.4, 142.2, 128.53, 128.49, 128.47, 128.4, 125.93, 125.85, 
79.1, 50.5, 37.7, 35.8, 35.3, 32.5, 28.6, 27.8. 
FT-IR (film): 3340, 2934, 1694, 1496, 1365, 1246, 1172, 746, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H32NO2: 354.2428, found: 354.2434. 
[]23D = +8.1 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl butyl (7,7,7-trifluoro-1-phenylheptan-3-yl)carbamate (56).  The title compound 
was synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-
butoxycarbonyl)amino)-4-phenylbutanoate and Zn-22.  The product was purified by column 
chromatography on silica gel (1:9 EtOAc/hexanes).  White solid. 
(S,S)-L2: 159 mg, 77% yield, 90% ee; (R,R)-L2: 157 mg, 76% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 9.7 min 
(minor), 16.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.24 (m, 2H), 7.23 – 7.14 (m, 3H), 4.30 (d, J = 9.4 Hz, 1H), 
3.76 – 3.55 (m, 1H), 2.77 – 2.57 (m, 2H), 2.22 – 1.95 (m, 2H), 1.86 – 1.73 (m, 1H), 1.71 – 1.52 (m, 
4H), 1.49 – 1.40 (m, 10H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 141.8, 128.6, 128.5, 127.2 (q, J = 276 Hz), 126.1, 79.4, 50.0, 
37.7, 34.9, 33.6 (q, J = 28.4 Hz), 32.5, 28.5, 18.6. 
19F NMR (376 MHz, CDCl3) δ –66.3.  
FT-IR (film): 3362, 2946, 1681, 1520, 1248, 1175, 746, 700 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H27F3NO2: 346.1988, found: 346.1986. 
[]23D = +9.3 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (6-((tert-butyldimethylsilyl)oxy)-1-phenylhexan-3-yl)carbamate (57).  The title 
compound was synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-
butoxycarbonyl)amino)-4-phenylbutanoate and Zn-23.  The product was purified by column 
chromatography on silica gel (1:9 EtOAc/hexanes).  Colorless oil. 
(S,S)-L2: 210 mg, 86% yield, 89% ee; (R,R)-L2: 205 mg, 84% yield, 87% ee. 
S–50 
SFC analysis: The ee was determined via SFC on a CHIRALCEL OD column (5% i-PrOH in 
supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L2: 4.9 min 
(major), 5.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.23 (m, 2H), 7.22 – 7.14 (m, 3H), 4.45 (d, J = 9.1 Hz, 1H), 
3.68 – 3.58 (m, 3H), 2.75 – 2.57 (m, 2H), 1.86 – 1.63 (m, 2H), 1.60 – 1.39 (m, 13H), 0.90 (s, 9H), 
0.05 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.2, 128.5, 125.9, 79.0, 63.0, 50.5, 37.8, 32.6, 31.9, 29.1, 
28.6, 26.1, 18.5, -5.2. 
FT-IR (film): 3348, 2929, 2857, 1702, 1365, 1252, 1174, 1101, 836, 776 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H42NO3Si: 408.2928, found: 408.2920. 
[]23D = +16.1 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
Ethyl 7-((tert-butoxycarbonyl)amino)-9-phenylnonanoate (58).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-9.  The product was purified by column chromatography on silica 
gel (1:4 EtOAc/hexanes).  Colorless oil. 
(S,S)-L2: 175 mg, 77% yield, 90% ee; (R,R)-L2: 168 mg, 74% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALCEL OD column (10% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L2: 4.7 
min (minor), 5.3 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.19 (m, 2H), 7.17 – 7.09 (m, 3H), 4.30 (d, J = 9.4 Hz, 1H), 
4.08 (q, J = 7.1 Hz, 2H), 3.59 (s, 1H), 2.71 – 2.51 (m, 2H), 2.24 (t, J = 7.5 Hz, 2H), 1.78 – 1.51 (m, 
4H), 1.47 – 1.24 (m, 15H), 1.21 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.8, 155.8, 142.2, 128.5, 128.4, 125.9, 79.0, 60.3, 50.6, 37.7, 
35.6, 34.3, 32.5, 29.1, 28.5, 25.6, 25.0, 14.4. 
FT-IR (film): 3368, 2935, 1711, 1514, 1366, 1247, 1174, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C22H36NO4: 378.2639, found: 378.2642. 
[]23D = +14.8 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
5-((tert-Butoxycarbonyl)amino)-7-phenylheptyl acetate (59).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-8.  The product was purified by column chromatography on silica 
gel (1:4 EtOAc/hexanes).  White solid. 
(S,S)-L2: 158 mg, 75% yield, 90% ee; (R,R)-L2: 162 mg, 77% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 12.0 min 
(minor), 17.7 min (major). 
S–51 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 2H), 7.21 – 7.13 (m, 3H), 4.33 (d, J = 9.4 Hz, 1H), 
4.04 (t, J = 6.6 Hz, 2H), 3.66 – 3.59 (m, 1H), 2.77 – 2.55 (m, 2H), 2.03 (s, 3H), 1.88 – 1.56 (m, 4H), 
1.54 – 1.32 (m, 13H). 
13C NMR (101 MHz, CDCl3) δ 171.3, 155.8, 142.1, 128.49, 128.45, 125.9, 79.1, 64.4, 50.5, 37.7, 
35.5, 32.5, 28.6, 28.5, 22.4, 21.1. 
FT-IR (film): 3354, 2943, 1732, 1520, 1366, 1244, 1174, 1043, 702 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C20H32NO4: 350.2326, found: 350.2327. 
[]23D = +15.4 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (8-fluoro-1-phenyloctan-3-yl)carbamate (60).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-10.  The product was purified by column chromatography on silica 
gel (1:3 EtOAc/hexanes).  White solid. 
(S,S)-L2: 152 mg, 78% yield, 90% ee; (R,R)-L2: 155 mg, 80% yield, 90% ee. 
After recrystallization using n-pentane/hexanes: (S,S)-L2: 139 mg, 90% ee → 119 mg, 86% 
yield (67% yield overall), 93% ee; (R,R)-L2: 101 mg, 90% ee → 79 mg, 78% yield (63% yield 
overall), 93% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (5% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 7.7 min 
(minor), 10.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.23 (m, 2H), 7.23 – 7.13 (m, 3H), 4.43 (dt, J = 47.3, 6.1 
Hz, 2H), 4.32 – 4.28 (m, 1H), 3.63 (s, 1H), 2.76 – 2.56 (m, 2H), 1.87 – 1.58 (m, 4H), 1.56 – 1.31 (m, 
15H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.2, 128.51, 128.48, 126.0, 84.2 (d, J = 164 Hz), 79.1, 
50.6, 37.8, 35.8, 32.6, 30.5 (d, J = 19.5 Hz), 28.6, 25.6, 25.3 (d, J = 5.4 Hz). 
19F NMR (376 MHz, CDCl3) δ –218.1. 
FT-IR (film): 3347, 2936, 1702, 1508, 1364, 1246, 1168, 1043, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H31FNO2: 324.2333, found: 324.2331. 
[]23D = +12.6 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (7-chloro-1-phenylheptan-3-yl)carbamate (61).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-11.  The product was purified by column chromatography on silica 
gel (1:4 EtOAc/hexanes).  White solid. 
(S,S)-L2: 160 mg, 82% yield, 90% ee; (R,R)-L2: 165 mg, 85% yield, 90% ee. 
S–52 
After recrystallization using n-pentane/hexanes: (S,S)-L2: 148 mg, 90% ee → 95 mg, 64% 
yield (53% yield overall), 96% ee; (R,R)-L2: 119 mg, 90% ee → 83 mg, 70% yield (59% yield 
overall), 96% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 10.5 min 
(minor), 12.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.24 (m, 2H), 7.23 – 7.14 (m, 3H), 4.31 (d, J = 9.4 Hz, 1H), 
3.64 (s, 1H), 3.54 – 3.50 (m, 2H), 2.77 – 2.57 (m, 2H), 1.87 – 1.60 (m, 4H), 1.55 – 1.36 (m, 13H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.1, 128.53, 128.47, 126.0, 79.2, 50.4, 45.1, 37.6, 35.1, 
32.5, 32.5, 28.6, 23.3. 
FT-IR (film): 3340, 2943, 1690, 1511, 1365, 1248, 1168, 682 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H29ClNO2: 326.1881, found: 326.1888. 
[]23D = +1.9 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
tert-Butyl (8-cyano-1-phenyloctan-3-yl)carbamate (62).  The title compound was 
synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-12.  The product was purified by column chromatography on silica 
gel (3:7 EtOAc/hexanes).  Colorless oil. 
(S,S)-L2: 165 mg, 83% yield, 82% ee; (R,R)-L2: 172 mg, 87% yield, 82% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALCEL OD column (10% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L2: 5.5 
min (minor), 7.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.16 (m, 2H), 7.15 – 7.06 (m, 3H), 4.23 (d, J = 9.4 Hz, 1H), 
3.54 (s, 1H), 2.68 – 2.49 (m, 2H), 2.25 (t, J = 7.2 Hz, 2H), 1.77 – 1.51 (m, 4H), 1.44 – 1.25 (m, 15H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.0, 134.4, 128.51, 128.45, 126.0, 123.6, 119.9, 79.2, 50.4, 
37.7, 35.7, 32.5, 28.5, 25.5, 25.2. 
FT-IR (film): 3350, 2935, 1690, 1517, 1365, 1247, 1170, 698 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C20H31N2O2: 331.2380, found: 331.2382. 
[]23D = +7.7 (c 1.0, CHCl3); 82% ee, from (S,S)-L2. 
 
 
tert-Butyl ((6S)-6,10-dimethyl-1-phenylundec-9-en-3-yl)carbamate (63, 64).  The title 
compound was synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-
butoxycarbonyl)amino)-4-phenylbutanoate and Zn-15.  The product was purified by column 
chromatography on silica gel (1:9 EtOAc/hexanes).  Colorless oil. 
(S,S)-L2: 185 mg, 83% yield, 5:95 d.r.; (R,R)-L2: 177 mg, 79% yield, 95:5 d.r. 
S–53 
HPLC analysis: The d.r. was determined via HPLC on a CHIRALPAK AD column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 5.7 min 
(major), 6.7 min (minor). 
NMR data for the product from (S,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.19 (m, 2H), 7.17 – 7.09 (m, 3H), 5.09 – 5.00 (m, 1H), 
4.26 (d, J = 9.3 Hz, 1H), 3.56 (s, 1H), 2.71 – 2.52 (m, 2H), 2.00 – 1.83 (m, 2H), 1.79 – 1.69 (m, 1H), 
1.64 (s, 3H), 1.56 (s, 3H), 1.48 – 1.21 (m, 15H), 1.20 – 1.04 (m, 2H), 0.82 (d, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.3, 131.2, 128.5, 125.9, 125.0, 109.8, 79.0, 51.0, 37.8, 
37.2, 33.1, 32.5, 28.6, 25.9, 25.7, 25.1, 22.5, 19.6, 17.8. 
NMR data for the product from (R,R)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.23 (m, 2H), 7.22 – 7.13 (m, 3H), 5.14 – 5.04 (m, 1H), 
4.30 (d, J = 9.4 Hz, 1H), 3.61 (s, 1H), 2.76 – 2.56 (m, 2H), 2.04 – 1.87 (m, 2H), 1.86 – 1.75 (m, 1H), 
1.68 (s, 3H), 1.60 (s, 3H), 1.47 – 1.29 (m, 15H), 1.20 – 1.07 (m, 2H), 0.87 (d, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 142.3, 131.3, 128.5, 125.9, 125.0, 109.8, 79.1, 51.0, 38.2, 
37.6, 37.1, 33.3, 33.0, 32.6, 28.6, 25.9, 25.7, 19.7, 17.8. 
FT-IR (film): 3346, 2963, 1691, 1524, 1454, 1365, 1247, 1167, 698 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H40NO2: 374.3054, found: 374.3052. 
[]23D = +15.1 (c 1.0, CHCl3); 5:95 d.r., from (S,S)-L2. 
[]23D = +6.0 (c 1.0, CHCl3); 95:5 d.r., from (R,R)-L2. 
 
 
4-((tert-Butoxycarbonyl)amino)-6-phenylhexyl (2S)-2-(4-isobutylphenyl)propanoate (65, 
66).  The title compound was synthesized according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-
((tert-butoxycarbonyl)amino)-4-phenylbutanoate and Zn-24.  The product was purified by 
column chromatography on silica gel (15:85 EtOAc/hexanes).  White solid. 
(S,S)-L2: 233 mg, 81% yield, 5:95 d.r.; (R,R)-L2: 240 mg, 83% yield, 95:5 d.r. 
HPLC analysis: The d.r. was determined via HPLC on a CHIRALPAK IC column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 10.0 min 
(minor), 12.3 min (major). 
NMR data for the product from (S,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 7.27 – 7.18 (m, 5H), 7.15 – 7.10 (m, 2H), 
4.22 (d, J = 9.5 Hz, 1H), 4.17 – 4.02 (m, 2H), 3.72 (q, J = 7.1 Hz, 1H), 3.65 – 3.55 (m, 1H), 2.74 – 
2.55 (m, 2H), 2.47 (d, J = 7.2 Hz, 2H), 1.94 – 1.81 (m, 1H), 1.78 – 1.58 (m, 4H), 1.53 (d, J = 7.2 Hz, 
3H), 1.51 – 1.21 (m, 11H), 0.93 (d, J = 6.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 174.8, 155.8, 142.0, 140.6, 138.0, 129.4, 128.5, 128.4, 127.3, 126.0, 
79.2, 64.5, 50.3, 45.3, 45.1, 37.8, 32.5, 32.0, 30.3, 28.6, 25.3, 22.5, 18.5. 
NMR data for the product from (R,R)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 2H), 7.27 – 7.18 (m, 5H), 7.16 – 7.10 (m, 2H), 
4.22 (d, J = 9.5 Hz, 1H), 4.16 – 4.04 (m, 2H), 3.72 (q, J = 7.1 Hz, 1H), 3.65 – 3.56 (m, 1H), 2.74 – 
S–54 
2.55 (m, 2H), 2.47 (d, J = 7.2 Hz, 2H), 1.94 – 1.81 (m, 1H), 1.77 – 1.57 (m, 4H), 1.53 (d, J = 7.2 Hz, 
3H), 1.51 – 1.20 (m, 11H), 0.93 (d, J = 6.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 174.8, 155.8, 142.0, 140.6, 138.0, 129.4, 128.5, 128.4, 127.3, 126.0, 
79.2, 64.5, 50.3, 45.3, 45.1, 37.8, 32.5, 32.0, 30.3, 28.6, 25.3, 22.5, 18.5. 
FT-IR (film): 3368, 2953, 1714, 1514, 1366, 1246, 1173, 700 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C30H43NNaO4: 504.3, found: 504.3. 
[]23D = +15.6 (c 1.0, CHCl3); 5:95 d.r., from (S,S)-L2. 




phenylhexan-3-yl)carbamate (67, 68).  The title compound was synthesized according to GP-
6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate and Zn-25.  
The product was purified by column chromatography on silica gel (15:85 EtOAc/hexanes).  
White solid. 
(S,S)-L2: 242 mg, 85% yield, 6:94 d.r.; (R,R)-L2: 236 mg, 83% yield, 95:5 d.r. 
HPLC analysis: The d.r. was determined via HPLC on a CHIRALPAK IC column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 6.6 min 
(minor), 8.2 min (major). 
NMR data for the product from (S,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 2H), 7.22 – 7.14 (m, 3H), 4.51 (td, J = 10.9, 4.4 
Hz, 1H), 4.31 (d, J = 9.4 Hz, 1H), 4.12 (t, J = 6.6 Hz, 2H), 3.71 – 3.45 (m, 1H), 2.75 – 2.56 (m, 2H), 
2.13 – 2.02 (m, 1H), 2.01 – 1.89 (m, 1H), 1.80 – 1.57 (m, 7H), 1.50 – 1.35 (m, 12H), 1.13 – 0.97 (m, 
2H), 0.96 – 0.84 (m, 7H), 0.78 (d, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 155.1, 142.0, 128.53, 128.45, 126.0, 79.2, 78.4, 67.6, 50.4, 
47.1, 40.9, 37.8, 34.2, 32.5, 31.5, 28.5, 26.2, 25.5, 23.4, 22.1, 20.8, 16.4. 
NMR data for the product from (R,R)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 2H), 7.22 – 7.14 (m, 3H), 4.51 (td, J = 10.9, 4.4 
Hz, 1H), 4.29 (d, J = 9.5 Hz, 1H), 4.12 (t, J = 6.4 Hz, 2H), 3.68 – 3.45 (m, 1H), 2.75 – 2.56 (m, 2H), 
2.11 – 2.02 (m, 1H), 2.02 – 1.90 (m, 1H), 1.82 – 1.56 (m, 7H), 1.51 – 1.35 (m, 12H), 1.13 – 0.97 (m, 
2H), 0.94 – 0.83 (m, 7H), 0.79 (d, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 155.1, 142.0, 128.55, 128.47, 126.0, 79.3, 78.4, 67.6, 50.4, 
47.1, 40.9, 37.9, 34.2, 32.5, 32.2, 31.5, 28.6, 26.2, 25.5, 23.4, 22.1, 20.9, 16.4. 
FT-IR (film): 3357, 2953, 1738, 1515, 1454, 1366, 1262, 1174, 959, 699 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C28H45NNaO5: 498.3, found: 498.3. 
[]23D = –26.5 (c 1.0, CHCl3); 6:94 d.r., from (S,S)-L2. 






butoxycarbonyl)amino)-7-phenylheptanoate (69, 70).  The title compound was synthesized 
according to GP-6 from 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate and Zn-16.  The product was purified by column chromatography on silica 
gel (1:4 EtOAc/hexanes).  White solid. 
(S,S)-L2: 358 mg, 87% yield, 16:84 d.r.; (R,R)-L2: 343 mg, 83% yield, 84:16 d.r. 
After recrystallization using n-pentane/hexanes: (R,R)-L2: 199 mg, 84:16 d.r. → 101 mg, 51% 
yield (42% yield overall), >99:1 d.r. 
HPLC analysis: The d.r. was determined via HPLC on a CHIRALPAK IC column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 8.9 min 
(minor), 14.6 min (major). 
NMR data for the product from (S,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.30 (m, 2H), 7.28 – 7.22 (m, 3H), 5.47 – 5.42 (m, 1H), 
4.74 – 4.62 (m, 1H), 4.46 (d, J = 9.3 Hz, 1H), 3.78 – 3.66 (m, 1H), 2.83 – 2.63 (m, 2H), 2.41 – 2.32 
(m, 4H), 2.13 – 1.86 (m, 6H), 1.78 – 1.39 (m, 26H), 1.27 – 1.05 (m, 12H), 1.00 (d, J = 6.5 Hz, 3H), 
0.95 (dd, J = 6.6, 1.9 Hz, 6H), 0.76 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.9, 155.8, 142.0, 139.7, 128.5, 128.4, 125.9, 122.7, 79.1, 73.9, 
56.8, 56.2, 50.1, 42.4, 39.8, 39.6, 38.2, 37.6, 37.1, 36.7, 36.3, 35.9, 35.0, 34.4, 32.5, 32.0, 31.9, 28.5, 
28.3, 28.1, 27.9, 24.4, 23.9, 22.9, 22.7, 21.4, 21.1, 19.4, 18.8, 11.9. 
NMR data for the product from (R,R)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.34 (m, J = 8.2, 6.8 Hz, 2H), 7.28 – 7.20 (m, 3H), 5.48 – 5.41 (m, 
1H), 4.75 – 4.63 (m, 1H), 4.48 (d, J = 9.3 Hz, 1H), 3.75 – 3.66 (m, 1H), 2.88 – 2.63 (m, 2H), 2.42 – 
2.31 (m, 4H), 2.19 – 1.85 (m, 6H), 1.82 – 1.39 (m, 26H), 1.28 – 1.06 (m, 12H), 1.00 (d, J = 6.5 Hz, 
3H), 0.95 (dd, J = 6.7, 1.8 Hz, 6H), 0.76 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.9, 155.7, 142.0, 139.7, 128.43, 128.40, 125.9, 122.7, 79.0, 73.9, 
56.7, 56.2, 50.1, 42.4, 39.8, 39.6, 38.2, 37.6, 37.1, 36.6, 36.3, 35.9, 35.0, 34.4, 32.5, 32.0, 31.9, 28.5, 
28.3, 28.1, 27.9, 24.4, 23.9, 22.9, 22.7, 21.4, 21.1, 19.4, 18.8, 11.9. 
FT-IR (film): 3368, 2941, 1722, 1366, 1248, 1174, 759 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C45H72NO4: 690.5456, found: 690.5451. 
[]23D = –18.7 (c 1.0, CHCl3); 16:84 d.r., from (S,S)-L2. 






yl)carbamate (71, 72).  The title compound was synthesized according to GP-6 from 1,3-
dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate and Zn-17.  The 
product was purified by column chromatography on silica gel (1:4 EtOAc/hexanes).  White 
solid. 
(S,S)-L2: 312 mg, 84% yield, 8:92 d.r.; (R,R)-L2: 327 mg, 88% yield, 94:6 d.r. 
HPLC analysis: The d.r. was determined via HPLC on a CHIRALPAK AD column (7% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 10.8 min 
(minor), 11.9 min (major). 
NMR data for the product from (S,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.20 (m, 2H), 7.19 – 7.10 (m, 4H), 6.65 (dd, J = 8.6, 2.9 
Hz, 1H), 6.58 (d, J = 2.8 Hz, 1H), 4.28 (d, J = 9.4 Hz, 1H), 3.98 – 3.81 (m, 6H), 3.64 – 3.56 (m, 1H), 
2.88 – 2.74 (m, 2H), 2.70 – 2.49 (m, 2H), 2.33 – 2.14 (m, 2H), 2.08 – 1.92 (m, 1H), 1.90 – 1.67 (m, 
7H), 1.67 – 1.55 (m, 2H), 1.55 – 1.24 (m, 20H), 0.85 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.0, 155.8, 142.2, 138.1, 132.7, 128.49, 128.46, 126.4, 125.9, 
119.6, 114.5, 112.1, 79.1, 67.8, 65.4, 64.7, 50.7, 49.5, 46.3, 43.7, 39.2, 37.7, 35.8, 34.4, 32.5, 30.9, 29.9, 
29.4, 28.6, 27.1, 26.3, 26.2, 25.8, 22.5, 14.5. 
NMR data for the product from (R,R)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.20 (m, 2H), 7.16 – 7.12 (m, 4H), 6.65 (dd, J = 8.6, 2.8 
Hz, 1H), 6.58 (d, J = 2.7 Hz, 1H), 4.27 (d, J = 9.4 Hz, 1H), 4.01 – 3.81 (m, 6H), 3.66 – 3.53 (m, 1H), 
2.89 – 2.72 (m, 2H), 2.72 – 2.52 (m, 2H), 2.34 – 2.14 (m, 2H), 2.05 – 1.94 (m, 1H), 1.90 – 1.67 (m, 
7H), 1.67 – 1.55 (m, 2H), 1.54 – 1.28 (m, 20H), 0.85 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.0, 155.8, 142.2, 138.1, 132.7, 128.49, 128.47, 126.4, 125.9, 
119.6, 114.5, 112.1, 79.1, 67.8, 65.4, 64.7, 50.7, 49.5, 46.3, 43.8, 39.2, 37.7, 35.8, 34.4, 32.5, 30.9, 29.9, 
29.4, 28.6, 27.1, 26.3, 26.2, 25.8, 22.5, 14.5. 
FT-IR (film): 3356, 2937, 1698, 1498, 1255, 1165, 1044, 754 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C39H56NO5: 618.4153, found: 618.4158. 
[]23D = +40.4 (c 1.0, CHCl3); 8:92 d.r., from (S,S)-L2. 




 VI.  Effect of Reaction Parameters 
 
General Procedure 8 (GP-8). 
Preparation of a solution of the catalyst: In a nitrogen-filled glovebox, an oven-dried 4 mL 
vial that contained a stir bar was charged with NiBr2⋅glyme (3.1 mg, 0.010 mmol, 10 mol%) and 
(S,S)-L1 (10.9 mg, 0.012 mmol, 12 mol%).  Next, THF (1.0 mL) was added, the vial was capped 
with a PTFE septum cap, and the mixture was stirred at room temperature for 30 min, leading 
to an orange, homogeneous solution. 
Cross-coupling: In a nitrogen-filled glovebox, a solution of the electrophile (0.10 mmol, 1.0 
equiv) in THF (1.0 mL) was added to the reaction mixture.  The vial was capped with a PTFE 
septum cap and taken out of the glovebox.  The reaction vial was then placed in an i-PrOH 
cooling bath at 0 °C, and the reaction mixture was stirred at 0 °C for 10 min.  Then, the 
alkylzinc solution (0.11 mmol, 1.1 equiv) was added dropwise via microsyringe over 3 min, 
during which the reaction mixture turned dark.  The punctures on the septum cap were 
sealed with grease, and the mixture was stirred at 0 °C for 36 h. 
Work-up: The reaction was quenched at 0 °C by the addition of MeOH (0.1 mL).  n-
Dodecane (23 μL, 0.10 mmol, 1.0 equiv) was added as an internal standard.  The reaction 
mixture was passed through a short pad of silica gel, with Et2O as the eluent.  The solvent 
was removed under reduced pressure, and the residue was purified by chromatography. 
 
General Procedure 9 (GP-9). 
Preparation of a solution of the catalyst: In a nitrogen-filled glovebox, an oven-dried 4 mL 
vial was equipped with a stir bar and charged with NiBr2⋅glyme (1.5 mg, 0.0050 mmol, 5.0 
mol%), (R,R)-L2 (1.8 mg, 0.0060 mmol, 6.0 mol%), and LiCl (8.5 mg, 0.20 mmol, 2.0 equiv).  
Next, THF (0.4 mL) was added, the vial was capped with a PTFE septum cap, and the mixture 
was stirred at room temperature for 30 min, during which it became a light-green, 
homogeneous solution. 
Cross-coupling: In a nitrogen-filled glovebox, DMAP (0.050 mmol, 0.50 equiv), the NHP 
ester (0.10 mmol, 1.0 equiv), and TMSCl (0.080 mmol, 0.80 equiv) were added sequentially to 
the reaction mixture as stock solutions in THF, totaling 1.2 mL THF (including 0.4 mL from the 
catalyst solution).  The vial was sealed with a septum cap and wrapped with electrical tape.  
Next, the vial was removed from the glovebox and cooled to 0 °C using an i-PrOH cooling 
bath.  After the white, heterogeneous reaction mixture had stirred at 0 °C for 10 min, the 
alkylzinc solution (0.12 mmol, 1.2 equiv) was added dropwise via microsyringe, resulting in a 
yellow, homogeneous solution.  The punctures on the septum cap were sealed with grease, 
and the mixture was stirred at 0 °C for 18 h. 
Work-up: The reaction was quenched at 0 °C by the addition of MeOH (0.1 mL).  The 
resulting mixture was allowed to warm to room temperature, and then 1-indanone (2.6 mg, 
0.020 mmol) was added as an internal standard.  The mixture was filtered through a small 
plug of silica gel, which was flushed with Et2O (10 mL).  The filtrate was concentrated under 
reduced pressure, and the residue was purified by chromatography.  
S–58 
Table S-1: 2-(1-Chloropropyl)isoindoline-1,3-dione was reacted with Zn-1 according to GP-
8.  The yields were determined via GC analysis, with n-dodecane as the internal standard.  
The ee values were determined via SFC analysis after purification by preparative thin-layer 
chromatography.  All data are the average of two experiments. 
 
Table S-1.  Effect of Reaction Parameters: An Alkyl Chloride as the Electrophile. 
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Table S-2: 1,3-Dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate was 
reacted with Zn-18 according to GP-9.  The yields were determined via LC-MS analysis, with 
1-indanone as the internal standard.  The ee values were determined via HPLC analysis after 
purification by preparative thin layer chromatography.  All data are the average of two 
experiments. 
 
Table S-2.  Effect of Reaction Parameters: An Alkyl NHP Ester as the Coupling Partner. 
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VII.  Studies of Functional-Group Compatibility 
 
Table S-3: 2-(1-Chloropropyl)isoindoline-1,3-dione was reacted with Zn-1 according to GP-
8, in the presence of 1.0 equiv of the additives shown below.  The additive was added after 
the addition of the 2-(1-chloropropyl)isoindoline-1,3-dione solution.  The yield of the 
coupling product and the percent recovery of the additive were determined via GC analysis, 
with n-dodecane as the internal standard.  The ee values were determined via SFC analysis 
after purification by preparative thin-layer chromatography.  All data are the average of two 
experiments. 
 
Table S-4: 1,3-Dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate was 
reacted with Zn-18 according to GP-9, in the presence of 1.0 equiv of the additives shown 
below.  The additive was added before TMSCl.  In addition to 1-indanone (2.6 mg, 0.020 
mmol), n-dodecane (23 μL, 0.10 mmol) was added as an internal standard after quenching the 
reaction.  The yields were determined via LC-MS analysis, with 1-indanone as the internal 
standard.  The percent recoveries of the additives were determined via GC analysis, with n-
dodecane as the internal standard.  The ee values were determined via HPLC analysis after 





































































a Determined through GC analysis. b Determined through SFC analysis. c 2.2 equiv of alkylzinc was used instead.
Cy
without additive:




































10 mol% NiBr2 • glyme
12 mol% (S,S)–L1





additive; recovery (%) a yield (%) a ee (%) b
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79% yield, 91% ee
a Determined through GC analysis. b Determined through LC-MS analysis. c Determined through HPLC analysis.
d 2.4 equiv of alkylzinc, 4.0 equiv LiCl, and 2.5 equiv TMSCl were used. The additive was recovered as the TMS ether.
0.5 equiv DMAP
0.8 equiv TMSCl
THF, 0 °C, 18 h
PhO
NHBoc












additive; recovery (%) a yield (%) b ee (%) c additive; recovery (%) a yield (%) b ee (%) c
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VIII.  One-Pot Reactions 
 
General Procedure 10 (GP-10). 
Preparation of the NHP ester: In the air, N-hydroxyphthalimide (97.9 mg, 0.60 mmol, 1.0 
equiv), the Boc-protected amino acid (0.60 mmol, 1.0 equiv), and DMAP (36.7 mg, 0.30 mmol, 
0.50 equiv) were added sequentially to an oven-dried 40 mL vial equipped with a cross-type 
stir bar.  The vial was capped with a PTFE septum cap and wrapped with electric tape.  The 
reaction vial was evacuated and back-filled with nitrogen (four cycles), after which a nitrogen-
filled balloon was attached.  THF (2.8 mL) was added via syringe, and the mixture was 
allowed to stir for 10 min, leading to an orange, heterogeneous mixture.  N,N’-
diisopropylcarbodiimide (112 µL, 0.72 mmol, 1.20 equiv) was then added dropwise via 
microsyringe over 2 min.  The mixture was stirred at room temperature for 1 h. 
Preparation of a solution of the catalyst: In the air, NiBr2glyme (9.3 mg, 0.030 mmol, 5.0 
mol%), (R,R)-L2 (10.7 mg, 0.036 mmol, 6.0 mol%), and anhydrous LiCl (52.1 mg, 1.20 mmol, 
2.00 equiv; because LiCl is hygroscopic, it is recommended to weigh the compound in a 
capped 4 mL vial in a glovebox, transfer the vial out of the glovebox, and pour the compound 
into the reaction vial) were added sequentially to an oven-dried 40 mL vial equipped with a 
cross-type stir bar.  The vial was then capped with a PTFE septum cap and wrapped with 
electrical tape.  The vial was evacuated and back-filled with nitrogen (four cycles), after 
which a nitrogen-filled balloon was attached.  THF (4.0 mL) was added via syringe, and the 
mixture was allowed to stir for 30 min, during which it became a light-green, homogeneous 
solution. 
Cross-coupling: The catalyst solution (4.0 mL) was transferred via syringe to the reaction 
vial containing the NHP ester, leading to an orange, homogeneous solution.  The vial was 
washed with THF (0.5 mL), which was also added to the reaction vial.  Next, TMSCl (61 µL, 
0.48 mmol, 0.80 equiv) was added via microsyringe, leading to a colorless, opaque mixture.  
The reaction vial was then placed in an isopropanol cooling bath at 0 °C, and the mixture was 
stirred at 0 °C for 10 min.  Then, the alkylzinc solution (0.72 mmol, 1.2 equiv) was added 
dropwise via syringe over 5 min, during which the reaction mixture became yellow and 
homogeneous.  The balloon was removed, and the septum cap was sealed with grease.  The 
mixture was stirred at 0 °C for 18 h. 
Work-up: The reaction was quenched with methanol (0.2 mL), and the mixture was passed 
through a plug of silica gel; the vial, the cap, and the silica gel were rinsed with Et2O.  The 




tert-Butyl (5-phenoxypentan-2-yl)carbamate (36).  The title compound was synthesized 
according to GP-10 from (tert-butoxycarbonyl)alanine and Zn-18.  The product was purified 
by column chromatography on silica gel (1:4 EtOAc/hexanes).  White solid. 
S–64 
(S,S)-L2: 112 mg, 67% yield, 90% ee; (R,R)-L2: 106 mg, 63% yield, 90% ee. 
 
 
tert-Butyl (5-phenoxy-1-phenylpentan-2-yl)carbamate (42).  The title compound was 
synthesized according to GP-10 from (tert-butoxycarbonyl)phenylalanine and Zn-18.  The 
product was purified by column chromatography on silica gel (1:3 EtOAc/hexanes).  White 
solid. 
(S,S)-L2: 135 mg, 63% yield, 90% ee; (R,R)-L2: 131 mg, 61% yield, 90% ee. 
After recrystallization using n-pentane/hexanes: (S,S)-L2: 112 mg, 90% ee → 95 mg, 85% 
yield (53% yield overall), >99% ee; (R,R)-L2: 111 mg, 90% ee → 96 mg, 86% yield (53% yield 
overall), >99% ee. 
 
 
Di-tert-butyl (8-phenoxyoctane-1,5-diyl)dicarbamate (43).  The title compound was 
synthesized according to GP-10 from N2,N6-bis(tert-butoxycarbonyl)lysine and Zn-18.  The 
product was purified by column chromatography on silica gel (1:3 EtOAc/hexanes).  White 
solid. 
(S,S)-L2: 170 mg, 65% yield, 90% ee; (R,R)-L2: 152 mg, 58% yield, 90% ee. 
 
 
tert-Butyl (1-(methylthio)-6-phenoxyhexan-3-yl)carbamate (44).  The title compound was 
synthesized according to GP-10 from (tert-butoxycarbonyl)methionine and Zn-18.  The 
product was purified by column chromatography on silica gel (3:7 EtOAc/hexanes).  White 
solid. 
(S,S)-L2: 105 mg, 52% yield, 92% ee; (R,R)-L2: 105 mg, 52% yield, 92% ee. 
After recrystallization using n-pentane/hexanes: (S,S)-L2: 76 mg, 92% ee → 56 mg, 74% 
yield (38% yield overall), >99% ee; (R,R)-L2: 82 mg, 92% ee → 68 mg, 83% yield (43% yield 
overall), >99% ee. 
 
 
Methyl 4-((tert-butoxycarbonyl)amino)-7-phenoxyheptanoate (47).  The title compound 
was synthesized according to GP-10 from 2-((tert-butoxycarbonyl)amino)-5-methoxy-5-
oxopentanoic acid and Zn-18.  The product was purified by column chromatography on silica 
gel (1:3 EtOAc/hexanes).  White solid. 




tert-Butyl 2-(3-phenoxypropyl)pyrrolidine-1-carboxylate (48).  The title compound was 
synthesized according to GP-10 from (tert-butoxycarbonyl)proline and Zn-18.  The product 
was purified by column chromatography on silica gel (1:9 EtOAc/hexanes).  White solid. 




IX.  Applications 
 
 
tert-Butyl (5-phenylpentan-2-yl)carbamate (73).  The title compound was synthesized 
according to GP-10 from (tert-butoxycarbonyl)-L-alanine and Zn-21.  The product was 
purified by column chromatography on silica gel (1:9 EtOAc/hexanes).  White solid.  The 
analytical data matched a literature report.5 
(S,S)-L2: 196 mg, 62% yield, 90% ee; (R,R)-L2: 209 mg, 66% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OJ column (2% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 7.4 min 
(minor), 9.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 2H), 7.22 – 7.13 (m, 3H), 4.35 – 4.30 (m, 1H), 
3.74 – 3.64 (m, 1H), 2.68 – 2.58 (m, 2H), 1.74 – 1.59 (m, 2H), 1.51 – 1.38 (m, 11H), 1.10 (d, J = 6.6 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.5, 142.4, 128.5, 128.4, 125.8, 79.0, 46.4, 37.0, 35.8, 28.5, 28.0, 
21.4. 
FT-IR (film): 3340, 2932, 1704, 1504, 1366, 1248, 1174, 1079, 699 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C16H25NNaO2: 286.2, found: 286.1. 
[]23D = –3.4 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
1-(5-Phenylpentan-2-yl)-3-(pyridin-2-yl)urea (74).  The title compound was synthesized 
according to a reported procedure.6  An oven-dried 40 mL vial was equipped with a stir bar 
and tert-butyl (5-phenylpentan-2-yl)carbamate (141 mg, 0.54 mmol, 1.0 equiv), and it was then 
sealed with a rubber septum cap.  The vial was placed under a nitrogen atmosphere by 
evacuating and back-filling the vial (three cycles), followed by the addition of anhydrous DCM 
(18 mL).  2-Chloropyridine (152 µL, 1.61 mmol, 3.0 equiv) was added, followed by 
trifluoromethanesulfonic anhydride (135 µL, 0.80 mmol, 1.5 equiv), and the reaction mixture 
was stirred at room temperature for 50 min.  Then, triethylamine (448 µL, 3.21 mmol, 6.0 
equiv) was added, followed by 2-aminopyridine (151 mg, 1.61 mmol, 3.0 equiv), leading to a 
dark red, homogeneous solution.  The reaction was stirred at room temperature for 20 h.  
The mixture was then concentrated, and the residue was purified by column chromatography 
on silica gel (5:7:8 EtOAc/hexanes/DCM).  Light-yellow oil. 
(S,S)-L2: 0.69 mmol scale, 117 mg, 60% yield, 91% ee; (R,R)-L2: 0.54 mmol scale, 98 mg, 65% 
yield, 91% ee. 
S–67 
HPLC analysis: The ee was determined via HPLC on a CHIRALCEL OD column (8% i-
PrOH in hexane, 1.0 mL/min); retention times for compound obtained using (S,S)-L2: 9.1 min 
(major), 11.3 min (minor). 
1H NMR (400 MHz, CDCl3) δ 9.23 (d, J = 7.8 Hz, 1H), 8.85 (s, 1H), 8.16 – 8.10 (m, 1H), 7.59 – 
7.50 (m, 1H), 7.32 – 7.21 (m, 2H), 7.21 – 7.12 (m, 3H), 6.90 – 6.79 (m, 2H), 4.12 – 3.98 (m, 1H), 
2.74 – 2.57 (m, 2H), 1.82 – 1.53 (m, 4H), 1.25 (d, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.8, 153.8, 146.0, 142.6, 138.3, 128.5, 128.4, 125.8, 116.6, 112.1, 
45.8, 36.9, 35.9, 28.0, 21.6. 
FT-IR (film): 3223, 3062, 1682, 1556, 1480, 1416, 1302, 1242, 777 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C17H22N3O: 284.2, found: 284.1. 
[]23D = +28.5 (c 1.0, CHCl3); 90% ee, from (S,S)-L2. 
 
 
(9H-Fluoren-9-yl)methyl (5-hydroxy-1-phenylpentan-2-yl)carbamate (75).  GP-10 was 
applied on a 1.2 mmol scale to (((9H-fluoren-9-yl)methoxy)carbonyl)-L-phenylalanine and Zn-
23 to generate the Fmoc-protected amine in situ.  The reaction was quenched with methanol 
(0.2 mL), and the mixture was passed through a short pad of silica gel, with Et2O as the eluent 
(~15 mL) into a 40 mL vial.  The resulting mixture was concentrated under reduced pressure 
to yield an orange oil. 
The vial was then placed under a nitrogen atmosphere by evacuating and back-filling the 
vial (three cycles), followed by the addition of methanol (5.0 mL).  A solution of HCl in 
methanol (1.25 M, 6.0 mL) was then added dropwise over 5 min. After the mixture had stirred 
at room temperature for 2 h, the methanol was evaporated under reduced pressure.  Water 
(10 mL) was added to the resulting residue, and the mixture was extracted with DCM (5 mL x 
3).  The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and 
concentrated.  The residue was purified by column chromatography on silica gel (7:3 
EtOAc/hexanes).  White solid.  The analytical data matched the literature report.7 
(S,S)-L2: 198 mg, 41% yield, 82% ee; (R,R)-L2: 176 mg, 37% yield, 79% ee. 
After recrystallization using THF/hexanes: (S,S)-L2: 198 mg, 82% ee → 136 mg, 69% yield 
(28% yield overall), >99% ee; (R,R)-L2: 176 mg, 79% ee → 128 mg, 73% yield (27% yield 
overall), >99% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IC column (40% i-PrOH in 
supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L2: 3.4 min 
(minor), 4.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.6 Hz, 2H), 7.51 – 7.42 (m, 2H), 7.32 (d, J = 7.5 Hz, 
2H), 7.27 – 7.18 (m, 4H), 7.15 – 7.04 (m, 3H), 4.52 (d, J = 9.0 Hz, 1H), 4.45 – 4.24 (m, 2H), 4.10 (t, J 
= 6.6 Hz, 1H), 3.86 (s, 1H), 3.61 – 3.37 (m, 2H), 2.78 – 2.42 (m, 2H), 1.56 – 1.45 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 156.1, 144.0, 141.4, 137.7, 129.5, 128.5, 127.7, 127.0, 126.5, 125.0, 
120.0, 66.3, 62.6, 51.9, 47.4, 41.4, 30.8, 29.0. 
FT-IR (film): 3316, 2933, 2360, 1686, 1534, 1250, 736 cm-1. 
S–68 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C26H28NO3: 402.2, found: 402.2. 
[]23D = +3.2 (c 1.0, CHCl3); >99% ee, from (S,S)-L2. 
 
 
(2-Isobutylpyrrolidin-1-yl)(phenyl)methanone.  GP-10 was applied on a 0.60 mmol scale 
to (tert-butoxycarbonyl)-L-proline and Zn-4 to generate the Boc-protected amine.  Next, 
trifluoroacetic acid (9.0 mL) was added at 0 °C, and the mixture was stirred at room 
temperature.  The consumption of the Boc-protected amine and the formation of the 
deprotected pyrrolidine were monitored via 1H NMR spectroscopy, using 1,3,5-
trimethoxybenzene as an internal standard. 
Yield by NMR of coupling and Boc-deprotection: 
(S,S)-L2: 69% yield; (R,R)-L2: 74% yield. 
After the reaction had stirred at room temperature for 2 h, the mixture was basified using 
10% aqueous NaOH.  The organic layer was separated, and the aqueous phases were 
extracted with DCM (10 mL x 3).  The combined organic layers were dried over Na2SO4, 
filtered, and concentrated to ~10 mL under reduced pressure.  To this solution was added 
triethylamine (502 µL, 3.60 mmol, 6.0 equiv) and benzoyl chloride (209 µL, 1.80 mmol, 3.0 
equiv), and the reaction mixture was stirred at room temperature for 14 h.  The mixture was 
then concentrated under reduced pressure and purified by column chromatography on silica 
gel (1:4 EtOAc/hexanes).  The resulting light-yellow solid was extracted with hexanes to yield 
the product.  Colorless oil. 
(S,S)-L2: 87 mg, 62% yield, 89% ee; (R,R)-L2: 93 mg, 67% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IC column (25% i-PrOH in 
supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L2: 7.9 min 
(minor), 8.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.56 – 7.32 (m, 5H), 4.46 – 3.81 (m, 1H), 3.73 – 3.29 (m, 2H), 
2.17 – 1.80 (m, 3H), 1.77 – 1.54 (m, 2H), 1.34 – 0.89 (m, 6H), 0.50 (dd, J = 104.9, 6.4 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 169.8, 137.6, 129.8, 128.2, 127.4, 56.0, 49.9, 43.3, 30.7, 25.8, 25.2, 
23.9, 22.0. 
FT-IR (film): 2955, 2870, 1633, 1578, 1415, 1166, 703 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C15H21NNaO: 254.1515, found: 254.1524. 
[]23D = +35.9 (c 1.0, CHCl3); 89% ee, from (S,S)-L2. 
 
 
1-(3-Iodopropoxy)-2-(3-methoxyphenethyl)benzene.  In the air, K2CO3 (2.3 g, 16.4 mmol, 
1.5 equiv) was added to a solution of 2-(3-methoxyphenethyl)phenol (2.5 g, 11.0 mmol, 1.0 
equiv) in DMF (30 mL) at room temperature, and the mixture was stirred at room temperature 





over 30 sec, and the reaction mixture was stirred at room temperature overnight.  The 
reaction was quenched with water, and the resulting mixture was extracted with DCM (30 mL 
x 3).  The combined organic layers were dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The residue was purified by column chromatography on silica gel (1:50 
Et2O/hexanes) to afford the product (2.4 g, 55% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.16 (m, 2H), 7.15 – 7.11 (m, 1H), 6.93 – 6.85 (m, 2H), 
6.82 – 6.71 (m, 3H), 4.05 (t, J = 5.7 Hz, 2H), 3.79 (s, 3H), 3.40 (t, J = 6.7 Hz, 2H), 2.98 – 2.81 (m, 
4H), 2.35 – 2.24 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 159.7, 156.6, 144.1, 130.4, 130.2, 129.4, 127.4, 121.0, 120.8, 114.3, 
111.3, 111.3, 67.2, 55.3, 36.6, 33.2, 32.7, 2.9. 
FT-IR (film): 2922, 2590, 2351, 1600, 1468, 1239, 1165, 1044, 916, 747, 695 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C18H22IO2: 397.1, found: 397.0. 
 
 
tert-Butyl 2-(3-(2-(3-methoxyphenethyl)phenoxy)propyl)pyrrolidine-1-carboxylate (77).  
The title compound was synthesized according to GP-10 from (tert-butoxycarbonyl)-L-proline 
and Zn-26 (Zn-26 was prepared according to GP-4).  The product was purified by column 
chromatography on silica gel (1:5 EtOAc/hexanes).  Colorless oil. 
(S,S)-L2: 135 mg, 51% yield, 88% ee; (R,R)-L2: 133 mg, 51% yield, 88% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IG-3 column (20% i-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (S,S)-L2: 5.0 
min (minor), 6.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.23 – 7.13 (m, 2H), 7.13 – 7.08 (m, 1H), 6.90 – 6.78 (m, 3H), 
6.77 – 6.71 (m, 2H), 4.07 – 3.91 (m, 2H), 3.91 – 3.73 (m, 1H), 3.78 (s, 3H), 3.45 – 3.25 (m, 2H), 2.96 
– 2.79 (m, 4H), 2.04 – 1.74 (m, 6H), 1.74 – 1.64 (m, 1H), 1.63 – 1.50 (m, 1H), 1.45 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.7, 157.0, 154.8, 144.3, 130.3, 130.0, 129.3, 127.3, 121.0, 120.4, 
114.4, 111.2, 111.1, 79.1, 67.9, 57.2, 55.2, 46.4, 36.5, 32.7, 31.7, 31.1, 28.7, 26.6, 23.5. 
FT-IR (film): 3486, 2920, 2354, 1682, 1046, 964, 744, 700 cm-1. 
LC-MS (ESI-MS) m/z [M+Na]+ calcd for C27H37NNaO4: 462.3, found: 462.2. 
[]23D = −30.1 (c 1.0, CHCl3); 88% ee, from (S,S)-L2. 
 
 
2-(3-(2-(3-Methoxyphenethyl)phenoxy)propyl)-1-methylpyrrolidine (78).  In the air, 
LiAlH4 (19.0 mg, 0.50 mmol, 5.0 equiv) was added to a solution of tert-butyl 2-(3-(2-(3-
methoxyphenethyl)phenoxy)propyl)pyrrolidine-1-carboxylate (43.9 mg, 0.10 mmol, 1.0 equiv) 
in THF (2.0 mL) at 0 °C, and then the reaction mixture was heated at reflux for 24 h.  The 
S–70 
reaction was quenched with water (5.0 mL) at 0 °C, and the reaction mixture was then 
extracted with Et2O (10 mL x 3).  The organic layer was dried over Na2SO4, filtered, and 
concentrated under reduced pressure to afford the product.  Colorless oil. 
(S,S)-L2: 35.7 mg, 99% yield; (R,R)-L2: 35.5 mg, 99% yield. 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.15 (m, 2H), 7.15 – 7.09 (m, 1H), 6.90 – 6.81 (m, 3H), 
6.78 – 6.72 (m, 2H), 4.06 – 3.95 (m, 2H), 3.79 (s, 3H), 3.14 – 3.04 (m, 1H), 2.99 – 2.83 (m, 4H), 2.32 
(s, 3H), 2.22 – 2.05 (m, 2H), 2.05 – 1.64 (m, 6H), 1.59 – 1.38 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 159.6, 157.0, 144.3, 130.4, 130.0, 129.3, 127.3, 121.0, 120.3, 114.3, 
111.13, 111.11, 68.0, 66.2, 57.4, 55.2, 40.5, 36.5, 32.8, 30.8, 30.3, 26.7, 21.9. 
FT-IR (film): 2915, 2353, 1600, 1469, 1247, 1168, 1111, 1047, 874, 752, 695 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C23H32NO2: 354.2, found: 354.2. 




X.  Mechanistic Experiments 
 
1. ESI-MS analysis using an alkyl chloride as the electrophile. 
 
 
Procedure.  In a nitrogen-filled glovebox, an oven-dried 4 mL vial that contained a stir bar 
was charged with NiBr2⋅glyme (3.1 mg, 0.010 mmol, 10 mol%) and (S,S)-L1 (10.9 mg, 0.012 
mmol, 12 mol%).  Next, THF (1.0 mL) was added, the vial was capped with a PTFE septum 
cap, and the mixture was stirred at room temperature for 30 min, at which time it had turned 
to an orange, homogeneous solution.  Then, a solution of 2-(1-chloropropyl)isoindoline-1,3-
dione (22.3 mg, 0.10 mmol, 1.0 equiv) in THF (1.0 mL) was added to the reaction mixture.  
The vial was capped with a PTFE septum cap and taken out of the glovebox.  The reaction 
vial was then placed in an i-PrOH cooling bath at 0 °C, and the reaction mixture was stirred at 
0 °C for 10 min.  Then, Zn-1 (0.11 mmol, 1.1 equiv) was added dropwise via microsyringe 
over 3 min, during which the reaction mixture turned dark.  The punctures on the septum 
cap were sealed with grease, and the mixture was stirred at 0 °C for 12 h.  Then, an ESI-MS 
analysis of the reaction was carried out on a Waters LCT Premier XE TOF MS in electrospray 
ionization (ESI+) mode. 
A1: HRMS (ESI-MS) m/z [M]+ calcd for C65H74N3NiO4Si2: 1074.4566, found: 1074.4572. 
A2: HRMS (ESI-MS) m/z [M]+ calcd for C65H74ClN3NiO4Si2: 1109.4254, found: 1109.4287. 
 
2. TEMPO trap experiments using an alkyl chloride as the electrophile. 
 
 
2-(1-((2,2,6,6-Tetramethylpiperidin-1-yl)oxy)propyl)isoindoline-1,3-dione.  In a nitrogen-
filled glovebox, an oven-dried 8 mL vial that contained a stir bar was charged with 
NiBr2⋅glyme (6.2 mg, 0.020 mmol, 10 mol%) and (S,S)-L1 (21.8 mg, 0.024 mmol, 12 mol%).  
Next, THF (2.0 mL) was added, the vial was capped with a PTFE septum cap, and the mixture 
was stirred at room temperature for 30 min, after which time it had turned to an orange, 
homogeneous solution.  Then, a solution of 2-(1-chloropropyl)isoindoline-1,3-dione (44.6 mg, 
S–72 
0.20 mmol, 1.0 equiv) in THF (2.0 mL) was added to the reaction mixture, followed by the 
addition of TEMPO (31.2 mg, 0.20 mmol, 1.0 equiv).  The vial was capped with a PTFE 
septum cap and taken out of the glovebox.  The reaction vial was then placed in an i-PrOH 
cooling bath at 0 °C, and the reaction mixture was stirred at 0 °C for 10 min.  Then, Zn-1 (0.22 
mmol, 1.1 equiv) was added dropwise via microsyringe over 3 min, during which the reaction 
mixture turned dark.  The punctures on the septum cap were sealed with grease, and the 
mixture was stirred at 0 °C for 36 h.  The reaction was quenched at 0 °C by the addition of 
MeOH (0.1 mL).  The reaction mixture was passed through a short pad of silica gel, with Et2O 
as the eluent.  The solvent was removed under reduced pressure, and the residue was 
purified by chromatography.  5.2 mg (0.015 mmol, 8% yield).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.80 (m, 2H), 7.80 – 7.65 (m, 2H), 5.69 (dd, J = 10.1, 5.0 
Hz, 1H), 2.58 – 2.38 (m, 1H), 2.30 – 2.08 (m, 1H), 1.56 – 1.39 (m, 3H), 1.38 – 1.22 (m, 6H), 1.18 (s, 
3H), 1.03 (s, 3H), 0.85 (t, J = 7.5 Hz, 3H), 0.74 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 168.6, 134.1, 132.3, 131.7, 123.6, 123.5, 87.5, 61.1, 59.2, 
40.26, 40.25, 33.5, 33.3, 23.8, 20.32, 20.26, 17.2, 10.1. 
FT-IR (film): 3470, 2934, 2352, 1715, 1456, 1360, 1022, 725 cm-1. 
LC-MS (ESI-MS) m/z [M+H]+ calcd for C20H29N2O3: 345.2, found: 345.2. 
 
3. Time-course experiments with an NHP ester as the coupling partner. 
 
Enantioenriched 1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoate was synthesized from enantiopure 2-((tert-butoxycarbonyl)amino)-4-
phenylbutanoic acid (both enantiomers are commercially available). 
Procedure.  In a nitrogen-filled glovebox, an oven-dried 4 mL vial was equipped with a 
stir bar and charged with NiBr2⋅glyme (1.5 mg, 0.0050 mmol, 5.0 mol%), (S,S)-L2 (1.8 mg, 
0.0060 mmol, 6.0 mol%), and LiCl (8.5 mg, 0.20 mmol, 2.0 equiv).  Next, THF (0.4 mL) was 
added, the vial was capped with a PTFE septum cap, and the mixture was stirred at room 
temperature for 30 min, during which it became a light-green, homogeneous solution.  
DMAP (6.1 mg, 0.050 mmol, 0.50 equiv) was added as a stock solution in THF, resulting in a 
light-blue, homogeneous solution.  The solution was then charged with a stock solution of 
rac, (R)-, or (S)-1,3-dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate 
(42.4 mg, 0.10 mmol, 1.0 equiv) in THF and a stock solution of TMSCl (8.7 mg, 0.080 mmol, 
0.80 equiv) in THF, totaling 1.2 mL THF (including 0.4 mL from the catalyst solution).  The 
vial was sealed with a septum cap and wrapped with electrical tape.  Next, the vial was 
removed from the glovebox and cooled to 0 °C using an i-PrOH cooling bath.  After the 
white, heterogeneous reaction mixture had stirred at 0 °C for 10 min, Zn-18 (0.12 mmol, 1.2 
equiv) was added dropwise via microsyringe, resulting in a yellow, homogeneous solution.  
The punctures on the septum cap were sealed with grease, and the mixture was stirred at 0 °C.  
After 4 h, the reaction was quenched at 0 °C by the addition of MeOH (0.1 mL).  The resulting 
mixture was allowed to warm to room temperature, and then 1-indanone (2.6 mg, 0.020 mmol) 
was added as an internal standard for LC-MS analysis.  The mixture was filtered through a 
S–73 
small plug of silica gel, which was flushed with Et2O (10 mL).  A portion of the filtrate (0.1 
mL) was diluted with acetone (total volume: 1 mL) and analyzed via LC-MS to determine the 
amount of product and remaining electrophile.  Another portion of the filtrate (0.1 mL) was 
diluted with acetone (total volume: 1 mL) and analyzed via SFC analysis to determine the ee of 
the remaining electrophile.  The remainder of the filtrate was concentrated under reduced 
pressure.  The pure product was isolated by preparative TLC on silica gel (1:4 
EtOAc/hexanes). 
SFC analysis of the remaining NHP ester: The ee was determined via SFC on a 
CHIRALPAK IE column (25% i-PrOH in supercritical CO2, 2.5 mL/min); retention times for 
(R)-enantiomer: 7.6 min, (S)-enantiomer: 9.3 min. 
HPLC analysis of the product: The ee was determined via HPLC on a CHIRALPAK IC 
column (3% i-PrOH in hexane, 1.0 mL/min); retention times for compound obtained using 
(S,S)-L2: 9.1 min (minor), 12.1 min (major). 
 
4. TEMPO trap experiments using an NHP ester as the coupling partner. 
 
 
tert-Butyl (3-phenyl-1-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)propyl)carbamate.  In a 
nitrogen-filled glovebox, an oven-dried 20 mL vial that contained a cross-type stir bar was 
charged with NiBr2⋅glyme (6.2 mg, 0.020 mmol, 5.0 mol%), (S,S)-L2 (7.1 mg, 0.024 mmol, 6.0 
mol%), and LiCl (33.9 mg, 0.80 mmol, 2.0 equiv).  Next, THF (1.6 mL) was added, the vial was 
capped with a PTFE septum cap, and the mixture was stirred at room temperature for 30 min, 
during which it became a light-green, homogeneous solution.  Next, a solution of 1,3-
dioxoisoindolin-2-yl 2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate (170 mg, 0.40 mmol, 
1.0 equiv) and DMAP (24.4 mg, 0.20 mmol, 0.50 equiv) in THF (3.2 mL) was added to the 
reaction mixture, followed by the addition of TMSCl (41μL, 0.32 mmol, 0.80 equiv) via 
microsyringe.  Next, TEMPO (62.5 mg, 0.40 mmol, 1.0 equiv) was added.  The vial was 
sealed with a septum cap and wrapped with electrical tape, and it was then removed from the 
glovebox and cooled to 0 °C using an i-PrOH cooling bath.  After the red, slightly opaque 
mixture had stirred at 0 °C for 10 min, Zn-18 (0.48 mmol, 1.2 equiv) was added dropwise via 
microsyringe over 5 min, resulting in a homogeneous, dark red solution.  The punctures on 
the septum cap were sealed with grease, and the mixture was stirred at 0 °C for 18 h.  Next, 
the reaction was quenched at 0 °C by the addition of MeOH (0.2 mL).  The resulting mixture 
was passed through a short pad of silica gel, with Et2O as the eluent.  A small aliquot was 
taken for HRMS analysis.  Attempts to isolate the TEMPO adduct by chromatography were 
unsuccessful. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H39N2O3: 391.2955, found: 391.3006. 
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XI.  Assignments of Absolute Configuration 
 
The configuration of the coupling product illustrated in Fig. 2B.1, 6, using (R,R)-L1, was 
determined via X-ray crystallography. 
 
 
Figure S-1.  Thermal ellipsoid plot at the 50% probability level. 
 
 
(R)-2-(1-Cyclohexyl-5-(4-(trifluoromethyl)phenyl)pentan-3-yl)isoindoline-1,3-dione (6).  
X-ray quality crystals were obtained by slow evaporation of a saturated solution in 
EtOAc/hexanes of a sample synthesized using (R,R)-L1.  A crystal of C26H28F3NO2 was 
selected and mounted in a nylon loop in immersion oil.  All measurements were made on a 
Bruker APEX-II CCD diffractometer with filtered Cu-Kα radiation at a temperature of 100 K.  
Using Olex2,8 the structure was solved with the XT9 structure solution program using direct 
methods and refined with the ShelXL10 refinement package using least squares minimization.  




Table S-5.  Crystal data for C26H28F3NO2.
Identification code V20056 
Chemical formula C26H28F3NO2 
Formula weight 443.49 g/mol 
Temperature 100 K 
Wavelength 1.54178 Å 
Crystal size 0.058 x 0.061 x 0.261 mm 
Crystal habit clear colourless block 
Crystal system orthorhombic 
Space group P 21 21 21 
Unit cell dimensions a = 5.3650(7) Å α = 90°  
b = 10.7237(14) Å β = 90°  
c = 38.480(5) Å γ = 90° 
Volume 2213.9(5) Å3 
 
Z 4 
Density (calculated) 1.331 g/cm3 
Absorption coefficient 0.837 mm-1 
F(000) 936 
Theta range for data collection 4.28 to 69.64° 
Index ranges -6<=h<=6, -12<=k<=12, -42<=l<=46 
Reflections collected 16610 
Independent reflections 3988 [R(int) = 0.0568] 
Coverage of independent reflections 97.8% 
Absorption correction Multi-Scan 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/5 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2018/3 (Sheldrick, 2018) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3988 / 196 / 320 
Goodness-of-fit on F2 1.073 
Final R indices 3783 data; I>2σ(I)  
all data R1 = 0.0462, 
wR2 = 0.0965 




Absolute structure parameter 0.03(9) 
Largest diff. peak and hole 0.213 and -0.258 eÅ-3 






(R)-2-(Nonan-3-yl)isoindoline-1,3-dione (17).  The absolute configuration of this 
compound has been established.11  The coupling product obtained with (S,S)-L1 has the (R)-
configuration, by comparison with the sign of the published optical rotation. 
Optical rotation: []22D = −6.1 (c 1.0, CHCl3); 89% ee, from (S,S)-L1. 
               Lit.: []26D = −17.2 (c 1.0, CHCl3); 99% ee for (R)-configuration. 
 
 
The configuration of the coupling product illustrated in Fig. 5A, 42, using (S,S)-L2, was 
determined via X-ray crystallography. 
 
 
Figure S-2.  Thermal ellipsoid plot at the 50% probability level. 
 
 
tert-Butyl (R)-(5-phenoxy-1-phenylpentan-2-yl)carbamate (42).  X-ray quality crystals 
were obtained by slow evaporation of a saturated solution in hexane/pentane of a sample 
synthesized using (S,S)-L2.  A crystal of C22H29NO3 was selected and mounted in a nylon loop 
in immersion oil.  All measurements were made on a Bruker APEX-II CCD diffractometer 
with filtered Cu-Kα radiation at a temperature of 100 K.  Using Olex2,8 the structure was 
solved with the XT9 structure solution program using direct methods and refined with the 
ShelXL10 refinement package using least squares minimization.  The absolute stereochemistry 




Table S-76.  Crystal data for C22H29NO3. 
Identification code V20066 
Chemical formula C22H29NO3 
Formula weight 355.46 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.053 x 0.140 x 0.246 mm 
Crystal habit colorless block 
Crystal system monoclinic 
Space group P 1 21 1 
Unit cell dimensions a = 10.191(2) Å α = 90°  
b = 9.3953(19) Å β = 115.106(8)°  
c = 11.509(3) Å γ = 90° 
Volume 997.8(4) Å3 
 
Z 2 
Density (calculated) 1.183 g/cm3 
Absorption coefficient 0.078 mm-1 
F(000) 384 
Theta range for data collection 2.92 to 28.29° 
Index ranges -13<=h<=13, -12<=k<=12, -15<=l<=15 
Reflections collected 44841 
Independent reflections 4963 [R(int) = 0.0712] 
Coverage of independent reflections 99.8% 
Absorption correction Multi-Scan 
Max. and min. transmission 0.9960 and 0.9810 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/5 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2018/3 (Sheldrick, 2018) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4963 / 1 / 238 
Goodness-of-fit on F2 1.082 
Final R indices 4598 data; I>2σ(I) R1 = 0.0359, wR2 = 0.0789  
all data R1 = 0.0411, wR2 = 0.0808 
Weighting scheme w=1/[σ2(Fo2)+(0.0340P)2+0.1542P] 
where P=(Fo2+2Fc2)/3 
Absolute structure parameter -0.1(3) 
Largest diff. peak and hole 0.192 and -0.202 eÅ-3 




tert-Butyl (R)-(4-phenylbutan-2-yl)carbamate (51).  The absolute configuration of this 
compound has been established.5  The coupling product obtained with (S,S)-L2 has the (R)-
configuration, by comparison with published optical rotation. 
Optical rotation: [α]23D = +10.6 (c 1.0, CHCl3); 81% ee, from (S,S)-L2.  
Lit.: [α]25D = +13.9 (c 0.9, CHCl3); 96% ee for (R)-configuration. 
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Figure 2B, entry 1
(S,S)L1: 88% ee









Figure 2B, entry 2
(S,S)L1: 92% ee









Figure 2B, entry 3
(S,S)L1: 91% ee









Figure 2B, entry 4
(S,S)L1: 81% ee










Figure 2B, entry 5
(S,S)L1: 90% ee










Figure 2B, entry 6
(S,S)L1: 88% ee










Figure 2B, entry 7
(S,S)L1: 89% ee










Figure 2B, entry 8
(S,S)L1: 90% ee









Figure 2B, entry 9
(S,S)L1: 91% ee









Figure 2B, entry 10
(S,S)L1: 90% ee









Figure 2B, entry 11
(S,S)L1: 88% ee










Figure 2B, entry 12
(S,S)L1: 90% ee










Figure 2B, entry 13
(S,S)L1: 91% ee












Figure 2B, entry 14
(S,S)L1: 88% ee












Figure 2B, entries 15 and 16
(S,S)L1: 95:5 dr









Figure 2B, entry 17
(S,S)L1: 89% ee










Figure 2B, entry 18
(S,S)L1: 95% ee









Figure 2B, entry 19
(S,S)L1: 94% ee









Figure 2B, entry 20
(S,S)L1: 91% ee










Figure 2B, entry 21
(S,S)L1: 89% ee









Figure 2B, entry 22
(S,S)L1: 89% ee









Figure 2B, entry 23
(S,S)L1: 90% ee










Figure 2B, entry 24
(S,S)L1: 89% ee










Figure 2B, entry 25
(S,S)L1: 90% ee









Figure 2B, entry 26
(S,S)L1: 91% ee










Figure 2B, entry 27
(S,S)L1: 90% ee










Figure 2B, entry 28
(S,S)L1: 91% ee









Figure 2B, entry 29
(S,S)L1: 89% ee













Figure 2B, entries 30 and 31
(S,S)L1: 96:4 dr

















Figure 2B, entries 32 and 33
(S,S)L1: 92:8 dr




























Figure 4B, entry 36
(S,S) L2: 90% ee


































































Figure 4B, entry 45
(S,S) L2: 91% ee


























































































































Figure 4B, entry 62
(S,S) L2: 82% ee














































































Figure 5B, entry 77
(S,S)L2: 88% ee
(R,R)L2: 88% ee  
 
 
 
 
 
 
